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Herpes Simplex Virus (HSV) – 1 also known as Human Herpes Virus (HHV) – 1 is a 
common infectious agent of humans which can cause a wide variety of clinical 
outcomes, ranging from mild mucocutaneous lesions to long term morbidity and 
possible mortality. Viral entry into cells requires the co-ordinated action of at least four 
HSV-1 envelope glycoproteins: gB, gD and the heterodimer gHgL. Dendritic cells (DC) 
are the most potent antigen presenting cells and are likely to encounter the virus early 
after entry into the host. HSV-1 readily infects DC leading to a series of both 
morphological and functional changes, and yet the pathway induced by HSV-1 that 
leads to DC maturation has not been elucidated. This thesis aims to understand the role 
of the viral entry glycoproteins in the activation of DC and the consequent initiation of 
an immune response. Defining this role has important implications not only in 
understanding immunopathogenesis, but also in the study of HSV-1 as an 
immunotherapeutic vector, and in the design of an efficient HSV-1 vaccine.
Monocyte-derived DCs (MDDC) were found to recognise and respond to the complex 
of four essential viral glycoproteins, independent of other viral proteins or nucleic acids. 
MDDC recognition of these four glycoproteins leads to the upregulation of a maturation 
phenotype and the production of type I interferon (IFN) as well as the induction of a 
strongly polarised TH1, IFN- dominated allogeneic T cell response. In contrast, 
monocyte-derived Langerhans cells (MDLC), display only partial maturation phenotype 
and do not produce type I IFN. Plasmacytoid DC (pDC) induce a strong type I IFN 
response to a viral infection, but not to the viral surface glycoproteins.
In the context of natural HSV-1 infection, these results suggest a model in which at the 
site of HSV-1 infection, different DC sub-populations respond differently to a viral 4
infection and to glycoproteins expressed on the surface of infected cells in order to 
provide an effective immune response.   To my wife and daughter6
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There are eight members of the Herpesviridae family known to infect humans. These 
are classified into three subfamilies: alpha, beta and gamma (Table 1.1). All share a 
common structure, composed of a large double-stranded linear DNA within an 
icosahedral capsid wrapped in a lipid bilayer membrane. 
Alpha Herpes Simplex Virus 1 (HSV 1)
Herpes Simplex Virus 2 (HSV 2)
Varicella zoster virus (VZV)
Human Herpes Virus 1
Human Herpes Virus 2
Human Herpes Virus 3
Beta Cytomegalovirus (CMV)
Roseolovirus
Human Herpes Virus 5
Human Herpes Virus 6
Human Herpes Virus 7
Gamma Epstein-Barr Virus (EBV)
Kaposi’s sarcoma-associated 
herpesvirus (KSHV)
Human Herpes Virus 4
Human Herpes Virus 8
Table 1.1: The subfamilies of the Herpesviridae family
A herpesvirus infection begins with attachment to and penetration of a host cell, 
followed by viral DNA migration to the host’s nucleus where the immediate-early genes 
are expressed even in the presence of inhibitors of protein synthesis. The immediate-
early genes are for the most part regulatory, switching on the expression of the early 
genes, which are made before DNA replication. The proteins made by the expression of 
the early genes include enzymes involved in DNA metabolism and replication. The late 
genes are expressed after DNA replication, and are encoded to make structural proteins 
including elements of the tegument.23
1.1. Pathogenesis of Herpes Simplex Virus – 1 infection
Herpes Simplex Virus (HSV) – 1/2 also known as the Human Herpes Virus (HHV) –
1/2 are two species of the herpes virus family. These viruses are able to infect humans 
of all ages, and it is estimated that 50% of the adult population in the UK are carriers of 
HSV-1, and 10% are carriers of HSV-2. The rates are much higher in other countries 
(UK Herpes Virus Association, accessed Sept. 2008). Infection results in a wide variety 
of clinical manifestations. The most common form of disease in humans are 
mucocutaneous lesions, which occur usually in or near themouth (cold sores or fever 
blisters), on the cornea (keratitis),or on genital tissues. Because the virus that causes the 
primarylesions establishes latent infections in sensory neurons and can be reactivated 
by appropriate stimuli,periodic recurrences of herpetic lesions are common and present
one of the troublesome aspects of infections with HSV. This said, a systemic evaluation 
of HSV-2 in asymptomatic individuals with no reported history of genital herpes 
suggest a high frequency of viral shedding and ability to spread the virus even when 
clinical signs are not visible (Wald et al., 2000). Less frequent, but with both serious 
long term sequelae, and some mortality, is disease affecting vital organs, including 
encephalitis in apparently normal adults,and disseminated disease in infants and 
immunocompromised individuals. 
Upon a primary infection, HSV-1 invades the neurons that innervate the infected site of 
infection, before being transported to the neuronal nuclei. Upon entry into the neuron 
the virion loses its envelope and most of the tegument proteins, leaving the capsid and 
some associated tegument to be transported to the nucleus. Current hypothesis suggest 
that the route of movement is retrograde (backward movement, from neural axon to 
neural cell body) along the microtubules (Diefenbach et al., 2008). It has been suggested 
that HSV-1 replicates briefly in neurons before establishing a latent infection in which 24
functional viral genomes are retained in neuronal nuclei without virus production. This 
latent infection may persist for the life of the individual and serves as a source of virus 
for recurrent diseases (Steiner, 1996). Upon reactivation, enveloped virions can exit the 
cell body directly, or be transported along the axon in an anterograde direction 
(Diefenbach et al., 2008).
1.2. HSV-1 structure  
Member of the Herpesviridae family of DNA viruses, HSV-1 carries a large linear 
double stranded genome of approximately 152 kb encoding approximately 80 viral 
genes. The viral genome is composed of unique long (UL) and unique short (US) 
segments, both flanked by inverted repeats (McGeoch et al., 1988). The HSV-1 genes 
fall into three categories depending on the kinetics of their transcription: “immediate 
early” (IE), responsible for preparing the cell for further viral gene expression; “early” 
(E), involved in the viral genome replication; and “late” (L), encoding the structural 
proteins (Weir, 2001). 
The virion carrying the viral genome is 120 – 300 nm in diameter consisting of an 
electron dense core containg the DNA enclosed by an icosahedral capsid. The capsid 
itself is surrounded by a proteinaceous layer - the tegument - and a lipid bilayer 
envelope on the surface containing the glycoprotein spikes (Grunewald et al., 2003)
(figure 1.1). Eleven virion proteins can be found on the surface of the envelope, 
including glycoprotein L, gM, gH, gB, gC, gK, gG, gJ, gD, gI, and gE. These proteins 
play important roles in virus attachment to target cells, cell entry, budding , cell-to-cell 
spread and viral immune evasion (Steven and Spear, 1997; Friedman, 2003) (Table 1.2).25
1.3. Entry
HSV and other members of the herpesviruses are distinct in that they rely on three 
different glycoproteins (gB, gH and gL) in addition to the receptor binding gD for 
fusion. HSV entry occurs when extracellular virions attach to the cell’s surface via gC 
and gB, and then bind to a gD receptor activating the membrane fusion machinery 
comprised of gB and the heterodimer gHgL (Campadelli-Fiume G et al., 2000; Spear, 
2004) (figure 1.2). It was generally believed that HSV entry into cells occurs by direct 
fusion of virion envelope with the outer plasma membrane (Wittels M and Spear, 1991). 
Recent reports have suggested, however, that at least three diverse pathways are 
implicated in HSV-1 entry into different cell types that are susceptible to infection: via 
direct fusion with the plasma membrane, via fusion within an acidic endosome, and via 
fusion within a neutral endosome. Fusion at the plasma membrane is known to occur in 
Vero cells in a pH-independent fashion (Koyama AH and Uchida T, 1987). In most cell 
types virion entry is by endocytosis, but this is also variable. For example, in HeLa 
cells, primary human keratinocytes, and CHO-K1 cells transfected with a gD-receptor, 
fusion with endosomal membrane requires a low pH environment (Nicola et al., 2003; 
Nicola et al., 2005). In contrast virus entry in mouse melanoma B78H1 cells, expressing 
a human gD receptor, also involves virion endocytosis, but fusion does not require low 
pH (Milne et al., 2005). Furthermore, this virus internalization in B78H1 melanoma 
cells is completely dependent upon the expression of the gD receptor. In each of these 
pathways, fusion requires gD, gB, gHgL and a gD receptor (Nicola and Straus, 2004). 
1.3.1. Cell surface interaction – glycoprotein C (and glycoprotein B)
The initial step in HSV-1 entry into mammalian cells is the attachment of the virus to 
the cell surface. gC and gB interact independently with heparan sulfate (HS) 26
proteoglycans to promote the initial attachment (Shieh et al., 1992; Herold et al., 1994; 
Laquerre et al., 1998). Yet these glycoprotein–HS interactions, although important, are 
not absolutely essential for viral entry, at least not in the infection of cultured cells. A 
virus mutant at the gB polylysine sequence responsible for the gB-HS interaction is still 
infectious, although virus binding is reduced; a virus lacking the gC glycoprotein is also 
still infectious (Herold et al., 1994; Laquerre et al., 1998). If both gB and gC are absent 
however, virus binding to cell surface is severely reduced (Herold et al., 1994). 
Infectivity is abolished completely in such virions, but this could be due to gB’s critical 
role in membrane fusion, rather than to virion attachment at the cell surface. Recent data 
suggest, however, that another receptor, independent of HS, may mediate interaction of 
gB with the cell surface, since a soluble form of gB was shown to interact with the 
surface of different cell types independent of HS (Bender et al., 2005). It has recently 
been suggested that the paired immunoglobulin like-type 2 receptor (PILR)-alpha 
associates with gB and mediates infection (Satoh et al., 2008). This receptor will be 
discussed further in section 1.3.3. 
1.3.2. Entry receptor interaction – glycoprotein D
Following gC and/or gB interaction with the cell surface, the next stage in viral entry 
requires the interaction of gD with one of several potential entry receptors. There are 
currently several known classes of receptors thought to play a role in entry.  The 
differential use of these receptors is important, and may help to account for the entry of  
HSV into such a wide range of different cell types (Richart et al., 2003; Krummenacher 
et al., 2004; Tiwari et al., 2006; Taylor et al., 2007). The binding of gD with its 
receptors is found to be essential for viral entry. Upon binding, gD is thought to transmit 
a signal to gB and/or gH-gL which interact with the cellular membrane to mediate cell 27
fusion (Cocchi et al., 2004; Krummenacher et al., 2005). It has recently been suggested, 
that the role of these receptors regardless of which receptor is used, is to trigger a 
common mechanism necessary for fusion. Studies have shown that soluble gD receptors 
are still able to initiate viral entry in non-susceptible CHO cell lines, suggesting that the 
attachment of gD with the cell surface is not essential (Kwon et al., 2006; Tiwari et al., 
2007). Detailed below are the three known receptors that bind gD.
Herpesvirus Entry Mediator (HVEM)
Member of the TNF receptor (TNFR) superfamily (Montgomery et al., 1996; Kwon et 
al., 1997), HVEM (also know as HveA) is expressed in a variety of tissues and cell 
types (Kwon et al., 1997; Tan et al., 1997; Harrop et al., 1998). The viral ligand for 
HVEM is gD (Whitbeck et al., 1997); HVEM’s physiological ligands are the TNF-like 
ligands LIGHT and lymphotoxin-alpha (Mauri et al., 1998) and, according to more 
recent studies, also BTLA (Sedy et al., 2005; Gonzalez et al., 2005). Characteristically 
for TNFR the extracellular domain of HVEM contains common cysteine-rich domains 
(Locksley et al., 2001) which have been found to be necessary for the binding of both 
gD (Whitbeck et al., 1997; Whitbeck et al., 2001; Connolly et al., 2002) and of 
HVEM’s physiological ligands (Sarrias et al., 2000). However, studies have shown that 
viral gD and the cellular ligands do not bind to the same region on HVEM (Compaan et 
al., 2005). In response to ligand binding, the cytoplasmic domain associates with TNF-
receptor associated factors (TRAF), specifically TRAF1, 2, 3 and 5 (Marsters et al., 
1997; Hsu et al., 1997), and the resulting signaling cascade is thought to contribute to 
the function and survival of many types of cells involved in immune responses (Harrop 
et al., 1998; Croft, 2003; Granger and Rickert, 2003).  In HSV infection, HVEM plays a 28
crucial role in viral entry and cell-cell spread (Montgomery et al., 1996; Whitbeck et al., 
1997; Roller and Rauch, 1998), and has been found to be specific for HSV gD binding. 
Nectin
Two members of the immunoglobulin (Ig) superfamily, nectin-1 (also termed HveC) 
and nectin-2 (also termed HveB) have been identified as another group of receptors 
known to play a role in HSV entry. All HSV strains tested to date are able to bind to 
nectin-1 and trigger entry (Krummenacher et al., 2004), but only a few isolates (HSV-2 
and certain mutant strains of HSV-1) were shown to utilize nectin-2 (Warner et al., 
1998; Lopez et al., 2000; Connolly et al., 2003). Nectin-1 is a type I transmembrane 
protein (Geraghty et al., 1998) containing three Ig-like extracellular domains, one 
variable (V) and two constant (C), followed by a transmembrane domain (TM) and a 
cytoplasmic tail (CT). It is expressed on a variety of cells, including epithelial and 
neuronal cells (Geraghty et al., 1998; Krummenacher et al., 2000; Haarr et al., 2001; 
Hung et al., 2002; Richart et al., 2003; Matsushima et al., 2003), and functions as a cell 
adhesion molecule forming the adherens junctions between epethilial cells (Takahashi et 
al., 1999; Sakisaka and Takai, 2004). 
In HSV infection, the N-terminal Ig-like variable domain is crucial for gD binding
(Krummenacher et al., 2000; Lopez et al., 2000; Martinez and Spear, 2002; Struyf et al., 
2002; Kwon et al., 2006). It has been suggested by several studies that HVEM and 
nectin-1 bind to closely located, yet different sites on gD, so that when the glycoprotein 
is in its bent structure forming a hairpin loop at the N-terminal it can bind to HVEM and 
in its extended form it binds to nectin-1 (Carfi et al., 2001; Connolly et al., 2005). 
Which of these receptors is more relevant in the infection of HSV in vivo is still to be
determined. Although studies have shown that both receptors are capable of mediating 29
HSV entry, studies on receptor expression demonstrate that each molecule of nectin-1 is 
more efficient at promoting entry compared to HVEM (Krummenacher et al., 2004). 
3-O-sulfated heparan sulfate
Another gD receptor identified to play a role in HSV-1 (but not HSV-2) entry is the 
non-protein 3-O-sulfated heparan sulfate, the product of certain 3-O- sulfotransferases 
(Shukla et al., 1999; Shukla and Spear, 2001; Tiwari et al., 2006). More recently, this 
product has also been shown to be important in polykaryocyte formation in human 
corneal fibroblasts used by the virus for cell-cell spread (Tiwari et al., 2007). 
1.3.3. Fusion – glycoprotein B and the gH/gL complex
The least understood stage in HSV-1 entry into mammalian cells is the fusion of the 
virion envelope with the cellular membrane. In the absence of gB, gH or gL, HSV 
cannot enter target cells (Cai WZ et al., 1988; Forrester A et al., 1992; Roop et al., 
1993; Chiang HY et al., 1994; Cocchi et al., 2004; Zago et al., 2004; Krummenacher et 
al., 2005). Since gD does not have the characteristics of a fusion protein, it is assumed 
that the central fusion machinery involves gB and the heterodimer gH/gL.
In many enveloped viruses the fusion process is performed by specific proteins in the 
viral membrane. To date, two completely unrelated structural classes have been 
identified, designated type I and type II fusion proteins. In the type I model (identified 
in orthomyxoviruses (Wilson IA et al., 1981; Bullough et al., 1994), paramyxoviruses 
(Yin et al., 2006), retroviruses (Fass D et al., 2006), filoviruses (Weissenhorn et al., 
1998) and coronaviruses (Xu et al., 2004), the fusion proteins form homotrimers that are 
cleaved proteolytically into a surface (SU) subunit and a transmembrane (TM) subunit 
anchored to the viral membrane. These fusion proteins are extended to a rodlike 30
structure in response to an activating trigger. A hydrophobic -helix fusion peptide at 
the N-terminus of the TM subunit is exposed and able to penetrate the target cell 
membrane. A further conformational change in the TM subunit brings together two 
heptad repeats (HR-1 and HR-2) located downstream of the fusion peptides, to form a 
coiled coil structure resulting a stable hairpin shaped conformation. This folding back of 
the fusion protein upon itself brings the viral and cellular membranes into close contact 
allowing the lipids in the outer membranes to mix (Colman and Lawrence, 2003; 
Jardetzky and Lamb, 2004; Schibli DJ and Weissenhorn W, 2004). In the type II model 
[applicable to flaviviruses (Rey et al., 1995; Modis et al., 2003) and alphaviruses 
(Lescar et al., 2001)], the fusion protein (which bears an internal fusion peptide able to 
penetratethe membrane of the target cell) is folded flat on the viral surface, in tight 
association with a second protein as a heterodimer. The activating cleavage occurs in 
the second protein. Receptor binding then leads to an irreversible rearrangement of the 
fusion protein into a trimer protruding from the viral envelope. This allows the 
penetration of the exposed hydrophobic hairpin loop into the target cell membrane 
(Colman and Lawrence, 2003; Jardetzky and Lamb, 2004; Kielian, 2006). A fold-back 
movement of the fusion protein then brings the viral and cellular membranes together.
The key role in HSV-1 fusion is thought to be played by the glycoproteins B and H, 
both conserved glycoproteins in the Herpesviridae family (Gompels U and Minson A, 
1986; Forrester A et al., 1992; Pereira L, 1994). Which one of these is actually 
performing membrane fusion and whether one is supporting the fusogenic activity of 
the other or if they both function at different stages or together, remains unclear. 
However recent advances in determining the structures of the HSV fusion glycoproteins 
indicate that herpesviruses may use some kind of intermediate mechanism with 
components similar to both type I and type II. 31
In its organization, gH resembles viral fusion glycoproteins - a possible -helix 
contained within the ectodomain of gH (at residues 377 to 397) has the characteristics 
of an internal fusion peptide, and two downstream heptad repeats (HR-1 and HR-2) 
could potentially interact and adopt a coiled coil conformation (Gianni et al., 2005a). 
Mutation or site deletion of the gH -helix results in HSV’s inability to enter cells; its 
replacement with heterologous fusion peptide of HIV gp41 or of VSV-G partially 
restores virus infectivity and gH fusion activity (Gianni et al., 2005b). Furthermore, 
disrupting the HR’s capability in forming coiled coils, also affected the ability of gH to 
function in the infectivity and cell fusion of cultured cells (Gianni et al., 2005b; Gianni 
et al., 2005a). Although gH/gL do not form trimers, these mutagenesis data suggest a 
function for gH as a fusion protein in HSV viral entry.
This being so, gH’s function is dependent on forming a heterodimer complex with gL, 
which acts as a gH chaperone for proper processing and gH trafficking to the viral 
envelope. HSV-1 gL is a short (224 amino acids) glycoprotein lacking a transmembrane 
domain (Peng et al., 1998a; Hutchinson et al., 1992; Dubin and Jiang, 1995). Upon 
expression in a complex with gH, gL is associated with the viral envelope; and, in the 
absence of gH, gL is secreted from cells (Dubin and Jiang, 1995). However, HSV-1 
virions lacking gL also lack gH, and although they bind to the cell surface, they do not 
penetrate the cellular membrane (Hutchinson et al., 1992; Roop et al., 1993). 
Like gH, gB is conserved among the Herpesviridae family (Pereira L, 1994). The 
recently solved crystal structure of HSV-1 gB (Heldwein et al., 2006) reveals a structure 
reminiscent of type I fusion proteins. On the other hand HSV gB is not cleaved 
proteolytically and may contain an internal fusion peptide similar to type II fusion 
proteins (Hannah et al., 2007). Studies involving virus-neutralizing monoclonal32
antibodies directed towards specific sites on the gB ectodomain found that antibodies 
that affected fusion reacted with residues in the mid-region of the ectodomain, 
suggesting that the gB ectodomain is exposed on the surface of the virion and may be 
required for viral penetration and cell fusion (Highlander SL et al., 1988; Heldwein et 
al., 2006).
Interestingly, the HSV gB ectodomain structure is homologous to the fusion protein G 
of Vesicular Stomatitis Virus (VSV) – a rhabdovirus with single-stranded RNA genome 
(Roche et al., 2006). As protein G of VSV is known to be the viral fusion protein, this 
structural similarity strongly suggests that gB might be the effector of membrane fusion 
during HSV entry. Because both VSV-G and HSV-gB have structural features of both 
class I and class II fusion proteins, they have been proposed to represent a new class of 
viral fusion proteins (Roche et al., 2006).
Recent studies using cell-cell fusion and virus-cell fusion assays have shown that HSV-
1-induced membrane fusion occurred through a hemifusionintermediate and that gD 
and gH/gL were sufficient to mediatehemifusion but not complete fusion (Subramanian 
and Geraghty, 2007). It is suggested that gB is necessary for completing the fusion 
process because complete fusion wasablated in the absence of gB. Regardless of which 
of gB or gH is the central fusion effector, these glycoproteins act in a complex with gD 
to promote virus fusion (Avitabile et al., 2007; Atanasiu et al., 2007). How they are 
activated by gD binding to cell receptors, and how this machinery functions, remains to 
be elucidated. 
The receptor(s), if any, used by these viral fusion proteins is still unclear. It has been 
suggested, as mentioned above, that gB may interact with PILR-alpha. Studies on PILR-
alpha transfectants, HSV-1 mutants, and primary cells expressing both gD receptors and 33
PILR indicated that both gB and gD receptors are required for HSV-1 infection (Satoh 
et al., 2008). However, to date there is no data which demonstrates the role of this 
receptor in fusion. This being so, several studies have tried to identify a cellular receptor 
for the complex gH/gL. The gH ectodomain contains a potential integrin-binding motif, 
thought to be responsible for the binding to cells. Indeed, modified gH/gL with a 
mutation in the integrin-binding-motif, abolished binding of gH to Vero cells; and CHO 
cells expressing the human v3-integrin bound efficiently to the gH/gL complex, 
suggesting the gH can bind to cells via v3-integrin (Parry et al., 2005). Recently, a 
new human protein, designated B5 was identified, which may function as an additional  
co-receptor for HSV entry (Perez-Romero and Fuller, 2005). This protein was found to 
contain hepatad repeats at the extracellularC terminus that are predicted to form an -
helix for coiled coils,similar to those in the cellular fusion proteins SNAREs, or in 
some viral fusion proteins. It is speculated that the complex gH/gL, which also form -
helices, may be the possible ligands for B5. 34
Figure 1.1: Schematic diagram of the HSV virion. The double stranded DNA is 
enclosed within an electron dense core enclosed within an icosahedral capsid. The 
capsid itself is surrounded by a proteinaceous layer - the tegument - and a lipid bilayer 
envelope on the surface containing the glycoprotein spikes. 
DNA tegument
lipid bilayer
glycoproteins
capsid35
Glycoprotein Gene Function
L UL1 Viral entry
M UL10 Virion assembly
H UL22 Viral entry
B UL27 Viral entry
C UL44 Virus-cell attachment; inhibition 
of complement
K UL53 Intracellular trafficking; viral 
budding
G US4 Uknown function
J US5 Protection from CTL apoptosis
D US6 Viral entry
I US7 Associates with gE; cell-cell 
spread; inhibition of antibody 
attack
E US8 Associates with gI; cell-cell 
spread; inhibition of antibody 
attack
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Figure 1.2: Model for direct HSV-1 entry by fusion with the cellular membrane.
Initially, although not mandatory (a), gB (together with gC) binds with heparan sulfate 
proteoglycans (HSPG) (b) or with an unknown gB receptor, independent of HS (c), 
allowing virus-cell attachment. This is followed by gD binding to a cell surface 
receptor: HVEM, nectin-1 or 3-O sulfated heparan sulfate (d). Then gD undergoes 
conformational changes and transmits a signal gB and/or gH-gL. gB possibly interacts 
with an unknown cell surface component. gB and gH-gL form the fusion machinery that 
interact with the cellular membrane (e). gB and gH-gL mediate cell fusion and entry of 
the viral capsid (f). How gB, gH and gL work together to achieve fusion is unclear and 
steps 3 and 4 are drawn hypothetically.  
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Step 4 – Fusion1.4. Immune response to HSV-1
The outcome of an HSV infection is partly determined by the host immune response. It 
is well established that immunocompromised individuals are more susceptible to viral 
infection. The response to HSV occurs in two phases, the innate and adaptive immune 
response. Traditionally, the innate immune system was considered as simply the non-
specific first line of defence. It is in the past decade or so, that more studies have 
suggested that despite its non-specificity, the innate immune response can distinguish 
between self and the infectious non-self and can be mobilised upon infection. The 
adaptive immune response on the other hand, acts as a second line of defence and 
affords a more pathogen specific protection as well as protection against re-exposure to 
the same pathogen.  
1.4.1. Innate immune response
Innate immune response against HSV-1 includes the generation and secretion of a 
variety of cytokines and chemokines which are responsible for the action of the innate 
immune cells. These cells act to limit the initial infection of the tissue, abrogate further 
propagation of the virus, and begin antigen presentation to initiate the activation of 
specific T and B cell response. The mechanisms used by the host in achieving these 
results are summerized below.
Skin and mucosal membrane
In addition to its function as a physical barrier to penetration, the skin as the body’s first 
line of defence against infection, includes at least two major functional immune 
components: the innate-inflammatory immunity, which involves the recognition of 
microbial compounds and the subsequent expression of pro-inflammatory cytokines and 38
interferons; and the “early warning” system which attracts the adaptive immune 
response (Meyer T et al., 2007).  
In natural human infection, HSV’s primary site of replication is within mucosal or 
epithelial cells. In the skin, epidermal keratinocytes play a vital role in the defence 
against the virus with the dermis as the site of the main inflammatory infiltrate 
(Cunningham AL and Noble JR, 1989). Studies have shown that infected keratinocytes 
express MHC class II antigens within 2 days of infection (Cunningham AL et al., 1985)
with production of various cytokines and chemokines, including beta chemokines, IL-
12, IL-10, IL-1alpha, IL-1beta and IL-6, early in the infection (Mikloska Z et al., 1998).  
It has been suggested that upon an infection the non-immune cells are primed to 
respond to low levels of viral infection by the induction of a small subset of interferon 
stimulating genes (ISG) which act to block viral replication without causing cellular 
damage. If, however, a threshold of viral entry is exceeded, interferon and 
proinflammatory cytokines are secreted warning surrounding cells to induce an antiviral 
response and to attract immune cells to the site of infection (Collins et al., 2004). 
NK cells
Natural killer (NK) cells are critical components of the innate immune system and have 
key roles in early immune responses to various pathogens (Yokoyama et al., 2004). 
Bone-marrow derived, they are capable of lysing cells without prior sensitization and 
release cytokines important in the regulation of the adaptive immune response. Upon a 
viral infection they undergo both nonspecific and viral specific proliferative phases, the 
latter related to NK cell-activation receptors for infected cells (Dokun et al., 2001; 
Yokoyama et al., 2004; Yokoyama et al., 2004). Severe infections with HSV have been 
observed in individuals lacking NK cells (Biron CA et al., 1989; Orange, 2002; Dalloul 39
et al., 2004) and several studies both in vitro and in vivo have demonstrated a NK cell 
role in innate response to HSV-1 (Fitzgerald et al., 1985; Rager-Zisman et al., 1987; 
Baraz L et al., 1999; Tanigawa et al., 2000). Recent reports, however, have suggested 
otherwise, demonstrating that immediate innate immune resistance to HSV infection, at 
least in the mouse model, is independent of NK cells (Vollstedt et al., 2004; Halford et 
al., 2005). 
Macrophages
Macrophages play an important role in the host defence mechanism. As phagocytic 
cells, macrophages act both in the initial killing defence and as activated antigen 
presenting cells. The role played by macrophages in the immune response to viruses is 
well established (Mogensen, 1979). Murine studies have also shown the presence of 
non-infected macrophages at the site of infection. These cells were found to be 
responsible for the secretion of TNF-alpha and type I IFN, necessary for the anti-viral 
response (Fields et al., 2006) and in the case of TNF-alpha, as a key mediator in the 
recruitment of cells to the site of infection, specifically via its effect on the local blood 
vessel endothelium and endothelial leukocyte interaction (Bradley JR, 2008).  
HSV-1 has also been shown in several studies to infect macrophages both in vitro and in 
vivo, but HSV does not actively replicate in either murine or human macrophages 
(Linnavuori K and Hovi T, 1983; Brucher J et al., 1984; Sarmiento, 1988). Nonetheless, 
infection of macrophages with HSV results in the partial activation of the cells as 
measured by upregulation of surface markers, low nitric oxide production and 
cytokine/chemokine secretion (Ellermann-Eriksen, 1993; Croen KD, 1993; Heise and 
Virgin, 1995; Paludan and Mogensen, 2001; Malmgaard et al., 2000; Paludan SR et al., 40
2001; Malmgaard et al., 2004), yet decreased ability to stimulate T cells (Hoves et al., 
2001).
Dendritic Cells 
Dendritic cells (DC) are the most potent antigen presenting cells (APC) with a 
remarkable ability to stimulate naïve T lymphocytes. Residing in most peripheral tissues 
throughout the body, in the absence of an inflammatory and immune response, 
immature DC function to sample and capture foreign antigens in the periphery. Upon a 
signal from a pathogen – whether by direct recognition of pathogens (through specific 
pattern-recognition receptors) or indirect sensing of infection (through inflammatory 
cytokines, internal cellular compounds, or ongoing specific immune responses), DC 
mature, expressing higher levels of cell surface MHC class I and II, which transforms 
them into efficient T cell activators, while at the same time losing their ability to pick up 
any more antigen. As non-proliferating cells, after a certain time course, these cells 
undergo apoptosis to be replaced by different cells (Banchereau and Steinman, 1998; 
Banchereau et al., 2000). A unique feature of DC is their ability to take up and present 
endosomal peptide fragments and deliver to the MHC class I, instead of the 
conventional route for exogenous antigens, which is to the MHC class II. This results in 
CD8 T cell priming. The process is known as cross-presentation (Guermonprez et al., 
2005), and  has several advantages for the host in viral infections, as  DC can take up 
and and present viral peptides from infected cells and then induces a cytotoxic T cell 
response. As these cells (DC) are the primary focus of the work described in this thesis, 
their biology will be discussed in more detail in section 1.6.
It is now well established that HSV infects human DC  (Salio et al., 1999; Kruse et al., 
2000; Pollara et al., 2003). Infection of immature DC by HSV-1 leads to a series of both 41
morphological and functional changes including partial maturation (as judged by 
surface phenotype), impairment of antigen presenting function and eventual apoptosis. 
However, the initial effect of HSV on DC, at least in monocyte derived DC (MDDC) in 
vitro, is the release of type I IFN (Pollara et al., 2004a). Studies have shown that type I 
IFN released by HSV infected DC, in addition to its anti-viral activity, also acts as a 
danger signal to bystander uninfected DC, inducing maturation, release of IL-12 and 
migration of DC cross-presenting antigen, which in turn induces paracrine maturation of 
further uninfected DC (Luft et al., 2002; Pollara et al., 2004a). This would promote a 
more effective TH1 immune response, and provide the link between the innate and 
adaptive phases.
Several pieces of evidence point to a role for DC in HSV-1 infection in vivo. In 
cutaneous HSV-1 infection, a large number of both myeloid DC and plasmacytoid DC 
precursors were shown to appear de novo in the circulation (Yoneyama et al., 2004a). 
Studies on mice of the C57 background (C57BL/6 and C57BL/10), shown to be the 
most resistant and best able to control HSV-1 infections (Simmons and Tscharke, 
1992), demonstrate the key role of these cells in the resistance to HSV-1 infections. 
Ablation of CD11c DC in these resistant strains of mice lead to the enhanced 
susceptibility to HSV-1 infection, including an increase in viral spread to the nervous 
system and an impaired activation of NK cells and both CD4
+ and CD8
+ T cells 
(Kassim et al., 2006). While pDC and to some extent mDC were shown to be 
responsible for the type I interferon production in response to HSV-1 infection (Lund et 
al., 2003; Krug et al., 2004; Hochrein et al., 2004). 
It is well established that DC express receptors known to associate with HSV-1 
glycoproteins, specifically HVEM and nectin-1 (Salio et al., 1999) and the different toll-42
like receptors (TLR). Recent data demonstrate a role for DC-SIGN in the interaction 
with gB and gC, although this receptor was shown not to be an entry receptor (de Jong 
MA et al., 2008). And yet, the route by which HSV-1 activates DC has not been fully 
characterized.
Cytokines and chemokines
Cytokines are important factors in the immune response and the protection against viral 
infections (Table 1.3). Yet, cytokines are also involved in the pathogenesis and 
development of symptoms of infection. Probably the most powerful anti-viral cytokines 
are the type I interferons (IFN) comprised in humans of 14 IFN-isoforms, a single 
IFN- and several other members such IFN-, -, - (Honda et al., 2006; Stetson and 
Medzhitov, 2006; Garcia-Sastre and Biron, 2006). In addition to their classical antiviral 
properties, type I IFN also contribute to the antiviralimmune response by stimulating 
the cytotoxic activity of NK cells, upregulation of MHC class I, maturation of bystander 
uninfected DC, and promotionof various T-cell functions, including expansion of the 
memorycells (Garcia-Sastre and Biron, 2006). Virtually all cells are able to produce 
type I IFN in response to viral infection, but plasmacytoid DC (discussed further in 
section 1.6.2) have been identified as the cells responsible for the majority of IFN 
production (Siegal et al., 1999; Asselin-Paturel et al., 2001; Colonna et al., 2002). In 
HSV-1 infection, type I IFN produced early in the infection by different cell types is 
known to block viral replication and to be important for the resistance against the virus 
(Mittnacht S et al., 1988; Leib et al., 1999; Noisakran et al., 2000). Defects in the IFN 
pathway in children with autosomal recessive deficiency of the intracellular protein 
UNC-93B have been shown to be linked with susceptibility to HSV encephalitis 
(Casrouge et al., 2006). 43
Type II IFN is a single cytokine, IFN-. Secreted primarly by NK cells, CD4
+ and 
CD8
+ T cells, IFN- has a wide range of immunomodulatory effects on both the innate 
and the adaptive immune response (Farrar and Schreiber, 1993). Although known to 
have direct anti-viral activity, IFN- is known more for its immunoregulatory functions 
(Boehm et al., 1997; Nansen et al., 1999; Henrichsen et al., 2005). Studies on null-
mutant mice (Bouley et al., 1995; Cantin et al., 1999) and human fibroblasts (Peng et 
al., 2008) have confirmed the importance of IFN- in host immune response to viral 
infections, including HSV-1.  
More recently, a type III IFN (IFN-) was discovered which has been shown to have 
anti-viral activity, via a mechanism similar to, but independent of, type I IFN (Kotenko 
et al., 2003; Sheppard et al., 2003). Studies on IFN- have indicated that not all viruses 
are susceptible (Ank et al., 2006) and not all cell types are responsive to this cytokine 
(Sheppard et al., 2003; Kotenko et al., 2003). However, the antiviral activity ofIFN-
against HSV-2 has been shown tobe comparable to that of IFN- in a systemic model 
(Ank et al., 2006; Ank et al., 2008).
The tumour necrosis factor (TNF) superfamily of cytokines plays an essential role in 
the early innate and subsequent adaptive immune responses against infections. The 
family includes several pro-inflammatory cytokines secreted by various different cell 
types. Pre-treatment of mice with TNF- has been reported to provide significant 
protection to lethal HSV-1 challenge in a pathway independent of interferon (Rossol-
Voth et al., 1991). Furthermore, TNF- deficient C57BL/6 mice show an increase in 
lethal encephalitis and viral replication in the brain (Sergerie et al., 2007). In humans, 
in-vitro studies on HSV-1 infected corneal epithelial cells demonstrate a rapid 44
upregulation of pro-inflammatory cytokines, including TNF-Li H et al, 
suggesting a possible role for this cytokine in-vivo in resistance to HSV. 
Other pro-inflammatory cytokines known to play a part in viral immunity include IL-
1, IL-6, and IL-12. In animal models, these cytokines have been shown to be secreted 
following HSV infection predominantly by lymphocytes, monocytes and macrophages. 
Studies have shown that upon HSV infection IL-1 and IL-6 are induced peaking at day 
10 post-infection (Shimeld et al., 1997). Studies on IL-1 knock-out (Sergerie et al., 
2007) and IL-6 knock-out (LeBlanc et al., 1999) mice demonstrate the importance of 
these cytokines in protection against HSV infection in the mouse model.
IL-12 is a heterodimer produced mainly by activated inflammatory cells in response to 
microbial infections to favour a Th1 response (Manetti R et al., 1993). Early in vitro
(Macatonia et al., 1995) and in vivo (Sousa et al., 1997) studies demonstrated rapid IL-
12 production by DC independent of IFN- or T cells. This being said, T cells, by direct 
contact and/or by IFN- and IL-4 production, enhance the IL-12 production by DC 
(D'Andrea A et al., 1995; Marshall et al., 1997; Cella M et al., 1996; Kalinski et al., 
2000). Produced by APC mainly via the TLRs (Medzhitov and Janeway, 1997), in 
humans, DC, but not pDC are the main producers of IL-12 in response to microbial 
molecules (Kadowaki et al., 2001). 
Chemokines, like cytokines are involved in the early host response to viral infection, 
with the inflammatory chemokines responsible for the attraction of immune cells. 
Several studies have looked at the chemokine response following HSV infection, 
demonstrating chemokine and chemokine receptor expression at both primary and latent 
infection sites, resulting in the recruitment of cells to and from the sites of infection 
(Cook WJ et al., 2004; Araki-Sasaki et al., 2006).45
Cytokine Producing Cells Function(s)
IL-1 monocytes; 
macrophages; DC
pro-inflammatory; stimulation of 
thymocytes proliferation; B cell 
maturation and proliferation
IL-2 TH1 cells Immunoregulatory; proliferation and 
activation of B, T and NK cells
IL-4  TH2 cells differentiation of naïve CD4
+ to TH2 cells; 
proliferation of activated B and T cells
IL-6 T cells; monocytes; 
fibroblasts; 
keratinocytes 
pro-inflammatory / anti-inflammatory; B 
cell differentiation and antibody 
production; inhibition of TNF- and IL-1 
and activation of IL-10
IL-10 monocytes; 
macrophages; DC; 
T and B cells; 
keratinocytes
anti-inflammatory; inhibiting synthesis of 
pro-inflammatory cytokines; ability to 
suppress antigen presentation by APC; 
enhances B cell proliferation and antibody 
production
IL-12 monocytes; 
macrophages; DC; 
B cells
pro-inflammatory; differentiation of naïve 
T cells to TH1 cells; stimulates production 
of IFN and TNF from T cells and NK 
cells 
IL-13 TH2 cells anti-inflammatory effects on monocytes 
and macrophages; inhibits expression of 
pro-inflammatory cytokines; important 
mediator in allergic inflammation
IL-17A TH17 cells T cell dependent inflammatory response; 
production of pro-inflammatory cytokines
IL-23 DC stimulates naïve CD4
+ T cells to 
differentiate to TH17 cells 
IFN- almost all cells anti-viral activity; maturation of bystander 
DC; up-regulation of MHC; stimulation of 
T and NK cells
IFN- TH1 cells; NK cells Immunoregulatory functions; increases 
antigen presentation on macrophages; 
suppresses TH2 activity
IFN- anti-viral activity; upregulation of MHC 
antigen expression
TNF- monocytes; 
macrophages; DC; 
B and T cells
pro-inflammatory; regulation of immune 
cells  
Table 1.3: Selected cytokines and their functions.46
1.4.2. Adaptive immune response
As mentioned, HSV has evolved several mechanisms to evade and inhibit the functions 
of both T and B cells. And yet, the appearance of HSV-specific antibodies and HSV-
specific T cells with cytotoxic function against infected cells suggest a vital function for 
the adaptive immune response in viral clearance.
Antibody response
Neutralizing antibodies following HSV infection have been documented for many 
years. In animal models antibody elicited by natural infection or immunization has been 
shown to modulate viral pathogenesis (McDermott MR et al., 1989; Bourne et al., 
2003). However, evidence for the protective effect of antibodies in humans is 
controversial: studies of neonatal infections have shown maternal antibody protection 
against viral transmission at birth in some cases, but not others, with antibodies specific 
to HSV-2 giving a better protection against neonatal transmission of HSV-2 than HSV-
1 (Brown ZA et al., 1991; Brown et al., 2007). Immunization with a HSV vaccine 
comprising recombinant HSV-2 gB and gD glycoproteins elicited high titers of 
neutralizing antibodies, but a modest level of protection, possibly due to a low antibody-
dependent cellular cytotoxicity (ADCC) observed (Corey et al., 1999; Stanberry et al., 
2002).
Antibody response has been detected against a wide array of viral proteins including 
envelope glycoproteins, tegument and capsid proteins (Ashley R et al., 1985; Ashley RL 
et al., 1994). Animal experiments suggest that viral glycoprotein gD induces 
neutralizing antibodies and several recombinant glycoprotein vaccines have been 
developed based on these findings (Cohen GH et al., 1972; Langenberg et al., 1995; 
Corey et al., 1999; Bernstein and Stanberry, 1999; Bourne et al., 2003). Furthermore, 47
mice immunized passively with monoclonal antibodies to gB, gC, gD and gH or 
immunized actively with either recombinant or synthetic viral glycoproteins were 
protected from lethal virus challenge (Balachandran N et al., 1982; Chan et al., 1985; 
Eisenberg RJ et al., 1985). HSV-1 specific neutralizing antibodies were also obtained in 
response to the gH-gL heterodimer, although their protective efficiency against viral 
challenge varied considerably in published studies (Browne H et al., 1993; Peng et al., 
1998b). However despite this, the development of an effective HSV vaccine based on 
antibody production remains elusive.  
CD4+ T cell response
CD4 T cells play an important role in the immune response. They express surface co-
stimulatory molecuelsm and produce an array of cytokines, which amplify the responses 
of other cells involved in both the innate and adaptive immune response. Three distinct 
subsets of activated cells are characterised by their abilities to produce different 
cytokines and by the function they perform. The differentiation (or polarisation) from 
the naïve CD4 cell to a specific subset is itself regulated by specific cytokines (figure 
1.3) (Jelley-Gibbs et al., 2008). The best characterised are the pro-inflammatory, IFN-
producing TH1 and the anti-inflammatory, TH2 subsets. Although, several studies have 
suggested a defence role for the TH2 subsets as well, specifically in parasitic helminths 
infections (Anthony et al., 2007). More recently a separate CD4 T cell subset has been 
identified, the IL-17 producing TH17, which is thought to play a part in the generation 
of auto-immunity as well as in the protection against pathogens such as Bordetella 
pertussis, Listeria monocytogenesis, Streptococcus pneumoniae, Mycobacterium 
tuberculosis, and Candida albicans, to name just a few (Khader et al., 2007; Curtis and 
Way, 2008).48
Another CD4 T cell subset, independent of the TH1, TH2 and TH17, are the 
CD4
+CD25
+Foxp3 regulatory T cells (Treg), whose function is to maintain immune 
system tolerance to self antigens. This is achieved by direct elimination of the cytotoxic 
cells, inhibition of proliferation and/or cytokine production in pathogenic T cells, as 
well as production of immunoregulatory cytokines such as TGFb and IL-10 (Askenasy 
et al., 2008). 
In HSV infection CD4 T lymphocytes are important mediators of immunity. Studies 
have shown the importance of CD4
+ cells in the protection of mice from HSV challenge 
(Manickan and Rouse, 1995; Milligan et al., 1998; Ghiasi et al., 2000; Harandi et al., 
2001). In humans, severe herpetic infections are seen in immunocompromised 
individuals with impaired T cell immunity (i.e. AIDS and transplant patients) (Chrétien 
F et al., 1996).  CD4
+ cells are stimulated following an HSV infection. They have been 
shown to present early in an infected epidermis secreting a variety of cytokines, the 
most important of which being IFN- (Mikloska Z et al., 1998). In vitro, IFN- partially 
reverses the down-regulation of MHC class I, permitinglysis of HSV-infected cells by 
CD8 cytotoxic T lymphocytes (Tigges et al., 1996), and induces MHC class II in 
epidermal cells rendering them more detectable by CD4
+ cells (Mikloska Z et al., 1996). 
In vivo, presence of high levels of IFN- was found to be important in the control of 
HSV infection, since mice lacking the ability to produce IFN- were more susceptible to 
infection (Yu et al., 1996). 
CD8+ T cell Response
Although infilitration of CD8
+ cells to the site of infection occurs after the infiltration of 
CD4
+ cells (Cunningham AL et al., 1985), studies of immunodeficient individuals 
suggest the the severity of HSV disease could be inversely correlated with the number 49
of HSV-specific CD8
+ T cells (Posavad et al., 1997). Infection with HSV involves the 
activation of CD8
+ T cells within the draining lymph nodes followed by their migration 
into the sites of infection where they act to clear the virus (Coles et al., 2002; van Lint et 
al., 2004). Studies have shown that these cells play a critical role in the primary antiviral 
immune response (Simmons and Tscharke, 1992; Dobbs et al., 2005) and in the latent 
viral reactivation in sensory neurons (Liu et al., 2000; Khanna et al., 2003).Figure 1.3: Polarisation of helper CD4 T cells.                                                                       
Helper CD4 T cell subsets, showing the cytokines responsible for their induction, and 
the effector cytokines that they produced. Cytokines that induce polarisation are shown 
with (↑), cytokines that inhibit polarisation are shown with ( T )1.5. Evasion of the immune response
The survival of a virus depends on the balance between the virus and the host. One 
strategy evolved by the herpes viruses is the development of a latent infection, hence 
“hiding” the virus from the immune response. But before the virus infects cells such as 
neurons to establish latency, it has to evade the early host response. Like many other 
viruses, HSV has evolved a series of mechanisms for the evasion and control of the 
host’s early immune system. Indeed the evolution of multiple viral immunomodulatory 
proteins suggests the immune system plays a major role in the HSV life cycle. The viral 
proteins with a possible role in immune evasion by HSV are discussed below:  
1.5.1. Inhibition of cytotoxic T cell activity
Cytotoxic T cells (CTLs) function to kill other “target” cells, this by inducting apoptosis 
of infected cells, and/or by the production of anti-viral cytokines. Avoiding recognition 
by CTLs is an attractive mechanism for immune evasion by pathogens.  HSV has 
evolved several mechanisms to withstand the action of CTLs, including the Us5 viral 
gene product, glycoprotein J which functions to suppress CTL induced apoptosis in a 
cell-type specific manner (Koyama and Miwa, 1997; Jerome et al., 1998; Jerome et al., 
2001), hence allowing the virus to complete an efficient replication cycle. Alternatively, 
HSV-1 infected CTL are silenced via fratricide-induced apoptosis (Raftery et al., 1999). 
This is a mechanism in which HSV infection of activated CTL results in these cells 
being more susceptible to “self-killing” by other HSV-specific CTL because MHC class 
I antigen presentation is not blocked in these cells following HSV infection. HSV 
induction of cell apoptosis has also been demonstrated in infected activated T cells (Ito 
M et al., 1997; Ito et al., 1997; Pongpanich A et al., 2004; Han et al., 2007), infected B 52
cells (Han et al., 2007), infected DCs (Pollara et al., 2003; Muller DB et al., 2004; 
Bosnjak et al., 2005) and infected macrophages (Fleck M et al., 1999). 
1.5.2. Inhibition of antigen presentation
Decreased antigen presentation can prevent both CD8
+ and CD4
+ T cell recognition of 
infected cells. One mechanism developed by the virus involves the decrease in 
maturation of DCs, the most potent APCs (Pollara et al., 2004a; Salio et al., 1999)
(discussed in detail in section 1.6). Other mechanisms involve a more specific decrease 
in expression and/or antigen presentation via both MHC class I and class II. These are 
schematically summarised in figure 1.4. 
The US12 gene (immediate early) of HSV-1 encodes infected cell protein (ICP) 47. 
This protein was found to interfere directly with MHC class I antigen presentation by 
binding to the cytosolic side of the transporter associated with antigen processing (TAP) 
molecules on the endoplasmic reticulum (ER), and hence, interfering with the 
translocation and loading of the peptides and antigen presentation to CD8
+ T cells (Hill 
et al., 1995; Fruh et al., 1995; Ahn K et al., 1996; Tomazin R et al., 1996). Recombinant 
ICP47 was found to protect HSV-infected human fibroblasts from CTL (Jugovic et al., 
1998). The role played by ICP47 in vivo is unclear, as this protein inhibits TAP little, if 
at all, in animal models (mouse, rat, guinea pig, or rabbit) unless applied at very high 
concentrations (50- to 100-fold higher than those requiredto inhibit human TAP) (Fruh 
et al., 1995; Ahn K et al., 1996; Tomazin et al., 1998; Jugovic et al., 1998). 
Nonetheless, HSV-1 lacking ICP47 showed reduced neurovirulence in mice with 
functional CD8
+ T cells, and characteristic neurovirulence in CD8
+ T cell-deficient mice 
(Goldsmith et al., 1998).  In order to address the limitations of in vivo studies, mice 
were infected with recombinant HSV expressing MCMV m152 or HCMV U11, two 53
herpesvirus proteins known to inhibit antigen presentation by murine MHC class I 
(Machold et al., 1997; Wagner et al., 2002). These rHSVs demonstrated increase in 
neurovirulence compared to wild-type virus, but no differences were seen in infection of 
MHC class I-deficient mice, or in mice in which CD8
+ T cells were depleted (Orr Mark 
T et al., 2005). This suggests that the increase neurovirulence in murine HSV infection 
may be due to inhibition of target cell recognition by antigen-specific CD8 cell. 
MHC class II is responsible for presentation of viral proteins that are internalized and 
degraded by antigen-presenting cells, hence initiating the CD4
+ T cell response 
(Germain and Margulies, 1993). Several studies have shown that HSV-1 glycoprotein B 
contains a MHC class II binding site sequence which inhibits peptide loading and 
prevents presentation of viral peptides (Sievers et al., 2002; Neumann et al., 2003). 
The mechanism of blocking peptide loading on to the MHC is not uncommon in human 
viruses (Vossen et al., 2002; Loch and Tampe, 2005). HCMV, another member of the 
Herpesviridae family, has been shown to use the US6 protein in inhibiting peptide 
transport via TAP (Kyritsis et al., 2001; Dugan and Hewitt, 2008). Other methods of 
MHC class I disruption include preventing initial proteosomal degradation (EBV, 
EBNA-1; HCMV, pp65); inhibiting the assembly of the MHC class I in the ER by 
degradation (HCMV, US2 and US11; HIV, Vpu; HHV-7, U21); inhibiting the transport 
of the MHC class I to the cell surface by retaining the MHC molecule in the ER 
(HCMV, US3, Us10; Adenovirus E19) and the Golgi (VZV, ORF66); and 
downregulating MHC class I molecules on the cell surface (KSHV, K3 and K5; HIV, 
Nef). Evasion mechanisms involving the MHC class II include, inhibition of MHC class 
II expression and processing.54
1.5.3. Inhibition of complement activation
The complement system plays an important role in removing infected cells by activating 
the complement cascade. Viruses have evolved several interference mechanisms to 
overcome this effect, including incorporating cellular componenets that protect the virus 
from the complement (Vaccinia); secreting complement-control proteins which can 
block the complement activity (Vaccinia and Variola). 
With respect to HSV-1, glycoprotein C is a receptor for the C3b fragment of the third 
component of complement (Friedman et al., 1984), reducing the activation of the 
alternative complement pathway by interfering with the C3b-C5 and the C3b-properdin 
interaction (Fries et al., 1986). In vitro, gC protects HSV infected cells from 
complement-mediatedlysis (Harris SL et al., 1990); in vivo studies have also shown a 
role in protecting the virus against complement attack (Lubinski et al., 1998; Lubinski et 
al., 1999), consistent with a role for gC in evasion of the immune response and viral 
survival. 
1.5.4. Inhibition of antibody attack
Binding of antibodies to epitopes on the surface of infected cells results in eventual 
lysis. In order to evade this pathway, viruses have evolved proteins (v-FcR) that bind to 
the Fc region of the host IgG, hence preventing free IgG to act on free virus or on viral 
infected cells. With respect to HSV-1, glycoprotein E and I form a hetero-oligomer 
complex which functions as a receptor (FcR) for the binding of the immunoglobulin G 
(IgG) by the Fc domain (Johnson et al., 1988; Bell et al., 1990). The anti-HSV IgG 
binds to the Fc receptor by its Fc end and to its target by its Fab end in a process called 
antibody bipolar bridging (Frank and Friedman, 1989; Van Vliet KE et al., 1992; 
Sprague Elizabeth R et al., 2006). Expression of gE alone is sufficient for low affinity 55
binding of IgG, but it is the gE-gI complex which allows for high affinity binding 
(Johnson et al., 1988; Dubin et al., 1990). This process has been shown to protect the 
virus and infected cells from the IgG-mediated immune response and complement-
dependent neutralization and antibody-dependent cell-mediated cytotoxicity (Frank and 
Friedman, 1989; Dubin et al., 1991). Using an HSV-1 mutant that lacked the viral FcR, 
this viral-host complex was shown to be important for viral immune evasion in vivo as 
well, since mutated virus was more susceptible to anti-viral IgG than wild-type virus 
(Nagashunmugam et al., 1998; Lubinski et al., 2002).
Other viruses, such as HCMV and MCMV have evolved similar mechanism by 
inducing the expression of surface glycoproteins which can bind to the Fc region of the 
host immunoglobulin (HCMV, TRL11/IRL11) (Lilley at al., 2001)
1.5.5. Destabilization of cellular mRNA
Many viruses induce upon infection inhibition of cellular functions in order to establish 
a cellular environment favourable for viral replication. With respect to HSV, infection 
results in the shutoff of host cellular protein synthesis soon after viral entry (Sydiskis 
and Roizman, 1966). Early shutoff is associated with several viral genes including the 
viral gene UL41, encoding the virion host shutoff (vhs) protein. This mechanism 
involves the degradation of cellular mRNA, resulting in the reduction of host protein 
synthesis by the destabilized cellular mRNA, and thus promoting the opportunity for 
enhanced translation of viral mRNA, and the resultant viral protein synthesis (Kwong 
AD et al., 1988). It has been suggested that vhs plays a part in the viral immune evasion 
mechanism by suppression of pro-inflammatory chemokines and cytokines (Suzutani et 
al., 2000), reduction in the levels of MHC class II (Trgovcich et al., 2002) and changes 
in MDDC function (Samady et al., 2003). 56
ICP27, a multifunctional regulatory IE protein, has also been reported to be a mediator 
of HSV-induced immune evasion. It has been implicated in shutdown of host protein
synthesis, host mRNA splicing inhibition and repression of host-genetranscription and 
mRNA stability (Hardwicke and Sandri-Goldin, 1994; Mogensen et al., 2004). More 
recent studies suggest a role in the decrease of STAT-1 phosphorylation, hence partially 
blocking STAT-1 translocation to the nucleus and production of a late IFN- (Johnson 
KE et al., 2008). In human macrophages, ICP27-deleted mutant virus clearly induced 
higher expression of IFN and chemokine genes than the wild-type virus (Melchjorsen et 
al., 2006). Other viral genes associated with destabilization of cellular mRNA include 
ICP4 acting to decrease host cell mRNA stability, thus contributing to shutoff of host 
protein synthesis, and to the inhibition of cytokine production (Mogensen et al., 2004; 
Melchjorsen et al., 2006); ICP0 which has been shown to inhibit nuclear accumulation 
of IFN regulatory factor (IRF)-3, as well as to interfere with IFN signaling (Mossman et 
al., 2000; Eidson et al., 2002; Harle et al., 2002; Melroe et al., 2004); and  ICP34.5 and 
Us11, both expressed at late stages of infection acting on the cellular RNA-activated 
protein kinase R (PKR), to prevent the shutoff of protein synthesis (He et al., 1997; 
Poppers et al., 2000).Figure 1.4: Schematic diagram of the MHC pathways, showing  potential sites of 
HSV-1 interference. a) Viral proteins in the cytosol are degraded by the proteosomes to 
small peptide fragments to be transferred to the ER via TAP. In the ER, these fragments 
are loaded on to the MHC class I to be presented on the plasma membrane to CD8
+ T 
cells. The ICP47 protein of HSV-1 may bind to the cytosolic side of TAP, hence 
interfering with the peptide fragment translocation to the ER and subsequent loading to 
MHC class I. b) Virus entering the cell via endocytosis go through a process of 
lysosomal degradation and subsequent loading on to the MHC class II to be presented 
on the plasma membrane to CD4
+ T cells. It has been suggested that HSV-1 gB contains 
a binding motif to MHC class II invariant chain (li) and HLA-DM, thus interfering with 
the correct function of the MHC and subsequent viral peptide loading.58
1.6. Dendritic cells
As mentioned above, DCs are the most potent APCs, active in the innate immune 
response and in the initiation of the adaptive immune response. It is well established 
today that DCs are activated via receptors, termed pattern recognition receptors (PRR) 
that recognize conserved pathogen associated molecular patterns (PAMP) - components 
commonly found on the pathogen that are not normally found in the host. In DCs, the 
PRR are chiefly members of the Toll-like receptor (TLR) family, although other 
receptors, including complement receptors (CR3; CD11b/CD18 and CR4; 
CD11c/CD18) (Thieblemont N et al., 1993; Bajtay et al., 2006), scavenger receptors 
(Mukhopadhyay S and Gordon S, 2004) and C-type lectins (Cambi and Figdor, 2003; 
Ebner et al., 2004) are also known to trigger activation of DC. There are currently 10 
known TLR in humans, and the number of known ligands for each receptor is 
increasing (Table 1.3). Studies of DC subsets isolated from humans and mice have 
suggested a difference in TLR expression on different subsets (Iwasaki and Medzhitov, 
2004; Flacher et al., 2006) (discussed below). Activation of the TLR leads to the 
induction of an inflammatory response via several distinct signaling pathways of which 
most (except for TLR3) are dependent on the adapter moclecule MyD88. The existence 
of individual pathways for each TLR may explain the distinct responses elicited by the 
different TLR agonists (Takeda et al., 2003).
1.6.1. Toll-Like Receptors
Over the years, TLR recognition of viral products has been studied, and six different 
TLR have been associated with virus recognition (Morrison, 2004). Originally it was 
expected that TLR3 which recognizes double-stranded RNA, would be the principal 
mediator of viral recognition (Alexopoulou et al., 2001). Studies have shown, however, 59
that TLR7 and TLR8, which recognize single-stranded RNA, are involved in the 
response to influenza virus and HIV (Heil et al., 2004; Diebold et al., 2004; Lund et al., 
2004) and more recently TLR7 was suggested to play a role also in MCMV (Zucchini et 
al., 2008); TLR4, which recognizes gram-negative bacterial lipopolysaccharide (LPS) 
was shown to play a role in respiratory syncytial virus (RSV) and mouse mammary 
tumor virus (MMTV) infections (Rassa et al., 2002; Kurt-Jones et al., 2000; Haynes et 
al., 2001); and TLR 2 and 9 were implicated in responses to members of the 
Herpesviridae (Compton et al., 2003; Tabeta et al., 2004; Krug et al., 2004; Lund et al., 
2003). More recently a TLR-independent pathway involving RIGI/MDA5 for viral 
recognition has been described (Yoneyama et al., 2004b; Kato et al., 2005). Studies on 
murine bone-marrow derived DC from control and knockout mice have shown the 
involvement of TLR2 and TLR9 in pathogenesis and DC inflammatory cytokine 
production in response to HSV-1 infections (Krug et al., 2004; Kurt-Jones et al., 2004; 
Hochrein et al., 2004; Mansur et al., 2005; Sato et al., 2006).
Additional PRR are also known to play a role in viral recognition by DC and initiation 
of an anti-viral response. Studies on HSV-1 infection of Vero cells, HeLa cells and 
BHK-1 cells suggest that the replication of a virus within these cell results in an 
accumulation of intracellular double-strandad RNA, which may trigger a host response 
mechanism (Weber et al., 2006). Retinoic acid-inducible gene I (RIG-I) is a highly 
inducible cytoplasmic member of the DExD/H box-containing RNA helicase family of 
proteins that signals antiviral responses following the binding of dsRNA (Yoneyama et 
al., 2004b). When activated, RIG-I triggers the activation of NF-B and IRF3/7, which 
in turn induce the production of antiviral type I IFN. This downstream signal is 
mediated via a recently identified CARD domain containg protein, mitochondrial anti-60
viral signaling protein (MAVS) (also known as IPS-1, CARDIF or VISA) (Seth et al., 
2005; Kawai et al., 2005; Xu et al., 2005; Sun et al., 2006).
Another DExD/H box RNA helicase family member found to interact with dsRNA is 
the melanoma-differentiation-associated gene 5 (MDA5) which acts in a similar way 
to RIG-I with some overlapping functions (Yoneyama et al., 2005). Both RIG-I and 
MDA5 can bind to dsRNA in vitro. However, in vivo the pathway depends on the virus, 
with RIG-I responding to Sendai virus, Newcastle disease virus, influenza A and 
Japanese encephalitis; and MDA5 responds to picornaviruses and to the synthetic 
dsRNA mimic, poly I:C (Kato et al., 2006).
Another cytosolic receptor that also evokes the nucleic acid-mediated activation of the 
innate immune response is DNA-dependent activator of IFN regulatory factors 
(DAI), also known as DLM-1/ZBP1 (Takaoka et al., 2007). Studies on this receptor 
have shown its direct interaction with DNA to bring about the trigger for type I IFN 
(Takaoka et al., 2007; Wang et al., 2008). Furthermore, knockout of DAI impairs the 
induction of type I IFN by dsDNA and HSV-1.61
Location Ligand(s)
TLR 1 cell surface (in 
association with TLR2)
Lipoproteins; Triacyl lipopeptides; 
Pam3CSK4
TLR 2 cell surface Bacterial lipoproteins; PG; viral 
glycoproteins
TLR 3 endosome Viral dsRNA; poly I:C
TLR 4 cell surface LPS; Lipid A; MPL; viral 
glycoproteins; HSP; Fibrinogen 
TLR 5 cell surface Flagellin
TLR 6 cell surface (in 
association with TLR2)
Diacyl lipopeptides; LTA; Zymosan;  
Pam2CSK4
TLR 7 endosome Viral ssRNA; Imiquimod; R848
TLR 8 endosome Viral ssRNA; R848; CL075
TLR 9 endosome Viral DNA; CpG-ODN
TLR 10 cell surface Unknown
Table 1.5: TLR ligands (adapted from Takeda and Akira, 2007). 62
1.6.2. DC Subtypes
Using a combination of monoclonal antibodies against cell surface molecules, together 
with micro-environmental observations, and in vitro studies, several different DC 
subtypes have been described both in humans and in animal models. The DC  
nomenclature depends on progenitors and precursors, anatomical localization and 
function, as well as phenotype (Nestle et al., 1993; Takahashi et al., 1998; Banchereau 
et al., 2000; Bendriss-Vermare N et al., 2001; McIlroy et al., 2001; Summers et al., 
2001; MacDonald et al., 2002; Wan H and Dupasquier M, 2005). 
Despite extensive research on the development of DC, the differentiation pathways that 
generate the different DC subtypes in vivo are still controversial. There are two current 
models for DC origin, suggesting the existence of two independent differentiation 
pathways originating from independent myeloid or lymphoid precursors; and 
alternatively, the existence of a common DC differentiation pathway that generates all 
subtypes from a common DC precursor. Based on direct and indirect experimental 
evidence a schematic diagram of the suggested human DC differentiation pathway is 
shown in figure 1.5 (Ardavin et al., 2001). Figure 1.5. Schematic diagram of the proposed origin of human DC subtypes.               
Two distinct models for the in vivo origin of human DC subtypes have been proposed. 
In the first, two independent differentiation pathways lead to the independent 
differentiation of conventional DC and Langerhans cells of myeloid origin or 
conventional DC, Langerhans cells and plasmacytoid DC of lymphoid origin. An 
alternative model suggests however, the existence of a common DC differentiation 
pathway that generates all subtypes from one common DC precursor.As HSV-1 infects predominantly the skin and mucosal surfaces, in this section the main 
emphasis will be on the two distinct DC subtypes found consistutively in normal skin: 
epidermal Langerhans cells (LC), and dermal DC (DDC) and on an additional DC 
subtype not normally present in the skin, but which migrates to the skin following 
inflammation: plasmacytoid DC (pDC) (fig. 1.6). 
Langerhans cells (LC) are a DC subset of the skin, constituting around 2% of the total 
cellular population of the epidermis (Katz FE et al., 1985). LC have a unique 
phenotype. They express E-cadherin, a type I transmembrane protein whose role is in 
cell adhesion to keratinocytes, langerin (CD207), a type II lectin transmembrane cell 
surface receptor and internal Birbeck granules. Upon antigen uptake, Langerin 
associates with the Birbeck granules and facilitates the routing from the cell surface into 
a nonclassical antigen-processing pathway (Valladeau et al., 2000). Interestingly, 
Langerin knockout mice lackBirbeck granules, but do not demonstrate defective 
immune responses,suggesting that the Langerin protein and Birbeck granules arenon-
essential for immunity to skin pathogens (Kissenpfennig et al., 2005). Despite this 
finding, Langerin and Birbeck granules remain thebest marker available for 
distinguishing LC from other DC subtypes.Furthermore, LC also express low levels of 
DC-SIGN (Ebner et al., 2004), but lack the macrophage mannose receptor (MMR) 
(Kato et al., 2000). 
The exact role of LC in peripheral immunity remains enigmatic. Early paradigms 
proposed that these cells signal the presence of antigen or pathogen in the epidermis to 
the adaptive immune system. According to this model, LC pick up antigen in the 
epidermis and then emigrate to skin draining lymph nodes (LN) via the dermal 65
lymphatics (Stoitzner et al., 2002).The presence of cells with dendritic morphology in 
the afferent lymph, which were presumably representative of this migration, led to the 
term “veiled cell” (Balfour BM et al., 1981). It was suggested that in the LNs, these 
cells display a mature phenotype and present theantigens to naive T cells (Stoitzner et 
al., 2002; Mayerova et al., 2004). 
However, this is not the only hypothesis that has been suggested to link peripheral 
antigen uptake and lymph node antigen presentation. Studies in mouse models did not 
support this view completely. Freshly isolated LC were not effective APC compared to 
DC (Inaba K et al., 1986; Katz DR and Sunshine GH, 1986). In experiments where 
infection was restricted to the mucosal and epidermal epithelia LC were not necessarily 
directly responsible for in vivo activation of specific T cells (Allan et al., 2003; Belz et 
al., 2004; Zhao et al., 2003; Lemos et al., 2004). On the basis of these studies, it has 
been suggested that LC play an indirect role, transporting antigen from the epidermis to 
the LNs, and then transferring the antigens to LN resident DC for antigen presentation 
and T cell priming. 
The origin of epidermal LC is two-fold. Under non-inflammatory conditions, epidermal 
LCs are renewed locally from a pool of precursors in the skin (Merad et al., 2002). In 
human studies this was first demonstrated in a study where dermal CD14
+ cells were 
shown to express Langerin and to acquire LC characteristics when cultured with TGF-
(Larregina et al., 2001). This was explored further in a mouse model, where in lethally 
irradiated mice that had received a bone-marrow transplant from a donor mouse, 
epidermal LC of host origin could be isolated for at least 18 months post-irradation, 
while DC in other organs were replaced almost completely within 2 months (Merad et 
al., 2002). Under inflammation however, following migration of LC into the skin-66
draining lymph nodes, these cells are replaced by blood-borne LC progenitors. More 
recent studies have shown that in the mouse model, these LC precursors are of myeloid 
orgin (Ginhoux et al., 2006).    
TGF-1 in the epidermal microenvironment is thought to be important for the 
phenotypic characteristic of LC (Strobl and Knapp, 1999), as TGF-1 knockout mice 
are completely devoid of epidermal LC, and these reappear after local injections of 
recombinant TGF-1 (Borkowski et al., 1996; Thomas et al., 2001). Because ex-vivo
purification of LC from human skin brings about a significant spontaneous maturation, 
possibly due to the cells’ dispatch and migration from the skin (Tchou et al., 2003), 
studies have focused mainly on mouse skin LC and LC-like cells derived from 
monocytes differentiated in the presence of TGF-(Geissmann et al., 1998; Geissmann 
et al., 1999; Nunez et al., 2004). 
Dermal DC (DDC) are a subtype of DCs of myeloid origin found within the 
extracellular matrix of the dermis. DDC can be distinguished from LC by the expression 
of MMR and DC-SIGN  (Turville et al., 2002; Santegoets et al., 2008), as well as the 
expression of the scavenger receptor CD36 and the coagulation factor XIIIa (Cerio R et 
al., 1989; Santegoets et al., 2008). In humans these cells lack the characteristic Langerin 
(CD207) of LC. In the mouse model however, studies have suggested that the dermis 
and skin draining lymph nodes contain langerin
low DC from a non-LC origin as well 
(Douillard et al., 2005; Ginhoux et al., 2007). 
Comparative studies with in vitro generated DC derived from CD14
+ monocytes 
suggest that the MDDC have a phenotype comparable to that of DDC (Grassi et al., 
1998), suggesting a) a myeloid precursor and b) relating DDC to what are commonly 
known as conventional DC (cDC), the most frequently studied form of DC. Although 67
originally considered to be of myeloid origin, since they could be produced from both 
human and mouse bone-marrow myeloid precursors (Reid et al., 1992; Inaba et al., 
1993; Caux et al., 1997), more recent studies suggest there may also be some cells that 
are derived from lymphoid progenitors (Martin et al., 2000; Bell and Bhandoola, 2008; 
Izon et al., 2001; Manz et al., 2001; Wu et al., 2001; Bell and Bhandoola, 2008). These 
DC are commonly found in the circulating peripheral blood and lymphoid tissues, as 
well as the skin, respiratory and gut mucosa, their specific functional capacities 
depending on the specific tissue.
Unlike DDC which are present in the dermis and express TLR1 – TLR8, ex-vivo 
epidermal LC express either low levels or undetectable TLR2, TLR4, TLR5 and TLR7 
(van der Aar et al., 2007; Takeuchi et al., 2003; Rozis et al., 2000), suggesting that these 
cells have low reactivity to bacterial pathogens, and thus presumably there is no 
unnecessary inflammatory response to harmless skin commensals.
Plasmocytoid DC (pDC) are specialized immune cells capable of producing large 
amounts of type I IFN and other pro-inflammatory cytokines in response to viral 
infections. In both human and mouse adults, they constitute around 0.2%-0.8% of total 
peripheral blood mononuclear cells, but are also found in primary and secondary 
lymphoid tissues, including thymus, tonsil, spleen, lymph nodes and bone marrow 
(Fitzgerald-Bocarsly and Feng, 2007). pDC are produced continuously in the bone-
marrow and circulate in peripheral blood to lymph nodes, mucosal-associated lymphoid 
tissues and spleen (Cella et al., 1999; Penna et al., 2002; Yoneyama et al., 2004a). 
Studies on pDC development suggest that Flt3L is the main cytokine driving their 
differentiation from haematopoetic stem cells (Pulendran et al., 1998; Blom et al., 2000; 
Brawand et al., 2002; Gilliet et al., 2002; Chen et al., 2004). Unlike MDDC (which in 68
vitro resemble DDC) that display TLR1-6, TLR10 and low levels of TLR7, and LC, 
which express either low levels or no TLR2, TLR4, TLR5 and TLR7 ( Rozis et al., 
2000; Kadowaki et al., 2001; van der Aar et al., 2007), pDC lack TLR2, TLR3 TLR4, 
TLR5, TLR6 and TLR8 completely, but do express the endosomal TLR7 and TLR9 
responsible for DNA and RNA virus recognition (Iwasaki and Medzhitov, 2004). 
Although activated pDC have been shown to present antigens and induce expansion of 
T cell population, albeit less efficiently than DC (Krug et al., 2003; Fonteneau et al., 
2003; Schlecht et al., 2004) their main function is in the early production of large 
amounts of type I IFN (Dalod et al., 2003). Figure 1.6: Schematic diagram of primary HSV-1 infection of the skin. The skin is 
the first line of defence against infection. The barrier function has two associated 
immune components: innate-inflammatory which involves the recognition of microbial 
compounds and the subsequent expression of pro-inflammatory cytokines and 
interferons; and the “early warning” system which attracts the adaptive immune 
response. a) In non-infected normal skin, the epidermis, made up of resident 
keratinocytes and LC, and the dermis, consisting of resident DDC and macrophages 
within an extracellular matrix serves as a barrier, the cells sampling for foreign antigens. 
b) In the presence of invasion by an infectious agent, these cells capture the foreign 
antigen releasing non-specific pro-inflammatory cytokines, and recruit more cells to site 
of infection, including pDC and NK cells. Upon activation, DC and macrophages 
migrate to the lymph nodes where they interact with other resident DC and naïve T and 
B cells to initiate the adaptive immune response.70
1.7. Hypothesis, aims and objectives of the thesis
In this introduction, the biology of HSV-1 and aspects of the immune response against 
it, specifically the role of DCs has been discussed. Previous studies from this laboratory 
have shown that wild-type HSV-1 infects DC readily leading to maturation as judged by 
surface phenotype. Infected DC produced IFN-, yet lose their antigen presenting 
abilities.  This was shown to be dependent on viral gene expression, as UV inactivated 
virus was shown to mature and activate DC (Pollara et al., 2004a), suggesting a role for 
the initial interaction between the viral surface and the cellular membrane in DC 
maturation. 
The aim of the work reported in this thesis is to investigate the hypothesis that the HSV-
1 glycoproteins necessary for viral entry into cells also play a role in DC activation, and 
therefore can play a role in the initiaition of an immune response.  
This hypothesis will be investigated by exploring three main objectives, each of which 
is reported and discussed in a separate chapter:
1. The development of an in vitro model in which individual HSV-1 glycoproteins 
are expressed independent from the rest of the virus and used to study the 
collaborative interaction between individual HSV-1 glycoproteins and MDDC. 
2. The investigation of the biological consequences of the HSV-1 glycoprotein-DC 
interaction as evidenced by the ability of the DC to activate T cells, to influence 
the signaling pathways that lead to cytokine secretion, and synthesize and 
release cytokines.  
3. The comperative investigation of the interaction of the HSV-1 glycoproteins 
with other DC subtypes, specifically LC and pDC.   CHAPTER 2 - MATERIALS AND METHODS72
2.1. Safety and Sterile Conditions
All tissue culture work was performed in a class II safety cabinet, using sterile 
techniques. 
2.2. Primary cells
Unless otherwise stated, all short and long term cell culture incubations were carried out 
at 37º C with 5% CO2. 
2.2.1. Monocyte-derived dendritic cells (MDDC) preparation
MDDC were prepared from 120 ml fresh wholeblood from healthy volunteers. The 
study was approved by the joint University College London/University College London 
Hospitals NHS Trust Human Research Ethics Committee (Ethics Committee Reference 
BRD/06/132) and written informed consent was obtained from all participants. 
Mononuclear cells separated onlymphoprep (Nycomed Pharma) (400 g, 30 mins, no 
brake), wereincubated in six-well tissue culture plates in Roswell Park Memorial 
Institute (RPMI) 1640 (Invitrogen Life Technologies, Paisley, U.K.)supplemented with 
10% FCS (v/v), 100 U/ml penicillin/streptomycin, and 2 mM L-glutamine (Clare Hall 
Laboratories, Cancer ResearchU.K.) as complete medium. After two hours incubation 
non-adherent cells wereremoved and the adherent cells were cultured in fresh complete 
mediumwith 100 ng/ml human recombinant granulocyte – macrophage colony 
stimulating factor (GM-CSF) and 50 ng/ml IL-4. After a four day incubation, loosely 
adherent cells were collectedand any remaining lymphocytes depleted by incubation 
with mouse anti-human monoclonal antibodies (mAb) against CD2 (to remove T cells 
and NK cells),CD3 (to remove T cells), and CD19 (to remove B cells), followed by 
anti-mouse IgG-coated immunomagneticDynabeads (Dynal Biotech, Merseyside, 
U.K.). The DCs were culturedfor a further three days in complete medium with fresh 73
GM-CSF andIL-4 at a concentration of 5 x 10
5 DC/ml and then used as immature DC 
for stimulation. Throughout the thesis these cells will be referred to as MDDC. 
2.2.2. Monocyte-derived Langerhans cells (MDLC)
MDLC were prepared similarly to MDDC, but with an addition of 10 ng/ml TGF-
(R&D systems) on day 0 and day 4 of culture. These cells will be referred to as MDLC. 
2.2.3. Plasmacytoid dendritic cells (pDC)
pDC were isolated from peripheral blood mononuclear cells (PBMC) by 
immunomagnetic cell sorting (MACS CD304 microbead separation kit, Miltenyi 
Biotec). 120 ml fresh peripheral blood was separated on lymphoprep (Nycomed 
Pharma) (400 g, 30 mins, no brake) and resuspended in MACS buffer (HBSS with 0.5% 
bovine serum albumin (BSA) and 2mM EDTA). pDC were then labled with microbeads 
conjugated to anti-CD304 (BDCA-4/Neuropilin) mouse monoclonal antibodies 
(Miltenyi Biotec) (4º C, 15 mins) and passed twice through a magnetic separation 
column (MS column, Miltenyi Biotec). pDC were counted and viability determined 
using trypan blue, before culture in complete medium.
2.2.4.  Epidermal Langerhans cells (LC)
Human dermatome sections of skin were recovered from mammoplasty surgery with 
informed consent and local ethical approval from Newcastle and North Tyneside Local 
Research Ethics Committee. Epidermal LC were a gift from M.P. Collin (University of 
Newcastle upon Tyne) and were isolated at the University of Newcastle upon Tyne as 
described previously (Collin MP et al., 2005). In brief, skin sheets were incubated in 
RPMI supplemented with Dispase 1mg/ml (Invitrogen) for 60 mins at 37º C. Epidermal 
sheets were then peeled from the dermis and rinsed in PBS. Fresh LC were isolated by 74
incubating the epidermal sheets in 0.25% trypsin for 10 mins at room temperature. 
Migratory LC were isolated by floating epidermal sheets for 72 hrs in complete RPMI 
medium supplemented with GM-CSF. 
2.2.5. DC stimulation
Day 7 purified immature MDDC / MDLC (2x10
5 – 5x10
5) were stimulated with 
Pam3Cys (100ng/ml; InvivoGen), polyinosine-polycytidylic acid (poly I:C) (50g/ml; 
InvivoGen), lipopolysaccharide (LPS) (100ng/ml; E. coli 0111:B4, InvivoGen), 
imiquimod (1mg/ml; InvivoGen), CL075 (1mg/ml; InvivoGen); CpG 
oligodeoxynucleotides (5g/ml; Coley) or recombinant human  soluble CD40 ligand 
(1g/ml; PeproTech). In most experiments known concentration of LPS were used as a
control. .
2.2.6. Preparation of T cells
T cells were obtained from the non-adherent population of PBMC which was described 
in section 2.2.1. Collected cells were resuspended at approximately 5x10
6 cells/ml and 
cyropreserved in FCS containing 10% dimethyl sulfoxide (DMSO) (v/v). Samples were 
frozen slowly to -70º C before transfer to liquid nitrogen for long term storage.
When required, cells were thawed rapidly (37º C water bath) and activated T cells, B 
cells, monocytes, and macrophages were depleted by incubation with CD19, HLA-DR, 
and CD14 mAb for 30 mins on ice. Cells were washed and then mixed with anti-mouse 
IgG-coated immunomagneticDynabeads (Dynal Biotech) and separated on magnetic 
columns. These T cells were used immediately after purification. 75
2.3. Cell and Tissue Culture
Similar to primary cells, all short and long term cell culture incubations were carried out 
at 37º C with 5% CO2. 
2.3.1. Cell lines
COS-7
The Cos-7 African green monkey kidney fibroblast-like cell line is derived from CV-1 
simian cells transformed by an origin-defective mutant of SV40. Cells were grown in 
Dulbecco's modified Eagle's medium (DMEM)supplemented with 10% FCS (PAA 
Laboratories, Linz, Austria) (v/v)and 100 U/ml penicillin/streptomycin (Sigma-Aldrich) 
(complete DMEM). 
Cos-7 cells were cultured until 80-90% monolayer confluency after which the cells were 
washed once with Hank’s Buffered Salt Solution (HBSS), detached from the surface of 
the flask with 2mM ethylene diamine tetra-acetic acid (EDTA) and re-cultured at ratio 
1:5 in complete DMEM.
BHK
The baby hamster (Golden Syrian) kidney 21, clone 13, fibroblast-like cell line was 
grown and cultured similarly to Cos-7.
CHO
The Chinese hamster ovary epithelial-like cell line was grown and cultured similarly to 
Cos-7. 76
HaCaT
The Human Keratinocyte Cell Line was grown and cultured similarly to Cos-7.
2.3.2. Storage of Cell Lines
For long term storage, cells were centrifuged at 300 g for 5 minutes and resuspended in 
90% fetal calf serum (FCS) and 10% DMSO (v/v). Freezing vials were slowly cooled to 
-70º C before transferred to liquid nitrogen for long term storage. For recovery, cells 
were thawed rapidly in 37º C water bath, diluted in HBSS and centrifuged at 300 g, 5 
minutes. The pellet was then resuspended in complete medium and transferred into a 
25cm
2 flask for culture.
2.3.3. Transfection
Cos-7 and CHO cells were cultured for 24 hrs before being transfected transiently using 
FuGENE 6 transfection reagent (Roche Diagnostics) with vectors expressing HSV wild-
type glycoproteins or mutant glycoproteins (table 2.3). Cells were cultured for a further 
48 hours to allow glycoprotein expression at the cell surface. Glycoprotein expression 
was verified by flow cytometry and confocal microscopy using glycoprotein-specific 
mAbs. 
Transfected cells were used to stimulate DC by over-layering DC on to the cells in 
complete medium at a ratio of 1:10 (discussed in detail in section 3.2.3). 
2.4. Virus preparation
2.4.1. Virus Growth
The Herpes Simplex Virus (HSV)-1 construct used was derived from strain 17+ 
containing a cassette of a cytomegalovirus(CMV) immediate early (IE) promoter that 77
drivesexpression of green fluorescentprotein (GFP; Clontech) anda respiratory 
syncytial viruspromoter that drives expressionof -galactosidase. This cassetteis 
inserted into theUL43 gene, as describedelsewhere (Coffin et al., 1996). This virus was 
a gift from R.S. Coffin (Biovex).
The virus was propagated on confluent BHK in complete DMEM. 48 hours post 
infection, cellular debris was removed by low speed centrifugation (3000 g, 30 mins, 
4°C). The supernatant was removed immediately and filtered through a double filter 
(0.65-µm and 0.45-µm, respectively) before being centrifuged at 16000 g for 2 hrs at 
4°C. The supernatant was discarded and the viral pellet was resuspended gently in 1 ml 
complete DMEM. The prepared aliquots were stored at –70°C until use. This virus 
preparation is referred to as HSV/GFP.
2.4.2. Viral infectivity assay
Viral infectivity and titre was determined by plaque assay on BHK cells. Serial dilutions 
[(10
4 to 10
9 plaque forming unit (pfu)] of virus in complete DMEM was added to a 
confluent BHK monolayer in a 24 well plate in quadruplicate. After 30 mins, 
incubation, 1ml of 1:3 (v/v) of 0.5% carboxymethyl cellulose : complete DMEM was 
added to each well. Cells were incubated for 48 hours and the number of plaques in 
each well were counted using fluorescence microscopy in order to determine virus titre 
in pfu/ml.  
The virus stock used in this entire study had a titer of 1 x 10
9 pfu/ml. 
2.4.3. Viral inactivation
HSV/GFP fixed virus was inactivated by incubating virus in 0.05% glutaraldehyde 
(Sigma-Aldrich) in PBS for 2 mins. Quenching of excess glutaraldehyde was performed 78
by diluting the virus in complete DMEM before adding to the cells. This virus is 
referred to as Fix-HSV/GFP. 
Neutralization of viral glycoproteins was performed using mouse monoclonal antibodies 
to HSV gD (LP2 and AP7), heterodimer gHgL (LP11) and gB (2153) (all gifts of Dr. H. 
Browne, University of Cambridge, UK). Virus was incubated with specific mAb for 30 
mins on ice before used to infect cells.  
2.4.4. Viral infection of DC
Immature day 7 MDDC / MDLC were infected with HSV/GFP. GFP expression upon 
infection was determined by fluorescence microscopy or flow cytometry 18-24 hours 
post infection.
2.5. Flow cytometry
All stained cells were acquired on a FACScan or FACS Calibur flow cytometer  using 
CellQuest software (BD Biosciences). For each sample at least 5000 events were 
acquired. Data was later analyzed with WinMDI v2.8 software (Joseph Trotter, Scripps 
Research Institute). 
2.5.1. Cell Surface Immunofluoresence 
For cell surface immunofluoresence, cells were harvested 18-24 hours post-stimulation. 
Non-specific antibody binding was blocked with 10% goat serum or 10% rabbit serum 
(20 mins, 4°C), depending on the secondary antibody.  DC were then stained for 
specific surface markers by incubation first with the relevant mAb (30 min, 4°C) 
followed by 1:50 diluted phycoerythrin (PE)-conjugated goat anti-mouse Ig or 
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse Ig (both from Dako) 
(30 min, 4°C). 79
For double staining, after removal of secondary conjugate cells were incubated in 1% 
mouse serum (10 mins, 4°C) and then further stained with directly-conjugated mAb 
(20mins, 4°C). Cells were washed and fixed in HBSS containing 3.7% 
paraformaldehyde (v/v). Samples were stored at 4°C in the dark and analyzed within 24 
hours. 
2.5.2. Intracellular Immunofluoresence 
For intracellular immunofluoresence staining, cells were harvested 1 hour or 5 hours 
post-stimulation. Cells were immediately fixed in tris buffered saline (TBS) containing 
3.7% paraformaldehyde (v/v) for 15 minutes. After washing off the fixative, non-
specific antibody binding was blocked with 10% goat serum (20 mins, 4°C). Cells were 
then stained for specific surface markers by incubation with directly-conjugated mAb 
(20 mins, 4°C), before permeablization with 90% methanol (10 minutes). After 
washing, non-spesific antibody binding was again blocked with 10% bovine serum 
albumin (BSA), and the cells stained by incubation with directly-conjugated mAb (20 
mins, 4º C). Cells were washed and resuspended in TBS. Samples were stored at 4°C in 
the dark and analyzed within 24 hours. 
2.6. T cell proliferation assay
All proliferation assays were performed using allogeneic T cells from HLA-mismatched 
donors and purified as described in section 2.2.5. Titrations of purified DC were 
incubated with 1 x 10
5 allogeneic T cells in flat-bottomed 96-well microtiter plates for 5 
days and then pulsed with 1 µCi of [
3H] thymidine (ICN Biomedical) for the final 18 h 
of culture. All proliferation assays were performed in triplicate wells. Cells were 
harvested, and T-cell proliferation was measured by liquid scintillation counting 
(Microbeta Systems). Results were expressed as counts per minute (cpm).80
2.7. ELISA
After 18-24 hour stimulation, supernatant was harvested and used to assay for DC 
cytokine secretion. IFNα was measured in cell supernatant using ELISA according to 
the company protocol (PBL Biomedical). Sandwich ELISA was set up for the detection 
of IL-12p70, IL-10 and TNF-. ELISA plates were coated overnight with 1g/ml IL-
12p70 (clone BT-21), IL-10 (clone JES3-9D7) or TNF-(clone MAb1) (all from 
eBioscience) or 4g/ml IL-8 (clone MAB208, R&D) capture antibodies in PBS at 4º C. 
The plates were blocked with 1% BSA in PBS for 2 hours at room temperature (RT). 
After washingwith PBS containing 0.05% Tween-20 (PBS-Tween), the plates were 
incubated with50 µl sample for 60 minutes at RT. Standards (eBioscience) werediluted 
in complete medium. The plates were washed in PBS-Tween and incubated with 1 
µg/mlbiotin anti-human IL-12 (clone C8.6), anti-human IL-10 (clone JES3-12G8) or 
anti-human TNF- (MAb11) (all from eBioscience) or 20 ng/ml IL-8 (clone BAF208, 
R&D) detection antibody in PBS-Tweenfor 60 minutes at RT. Next, the plates were 
again washed with PBS-Tweenand incubated with 50 µl streptavidin horseradish 
peroxidase (HRP)-conjugated (R&D Systems) in PBS-Tween for 30 min at RT. After 
further washing,HRP presence was detected using tetramethlybenzidine (TMB) 
substrate (eBioscience). Colorimetric reactions (450nm) were quantified immediately 
on the MRX Revelation plate reader using the Revelation v4.21 software (Dynex 
Technology) for analysis. All concentrations were determined in accordance with the 
standards (fig. 2.1). 
For T cell cytokine secretion, supernatants were collected 24 hours and 6 days post T 
cell-DC co-culture. Sandwich ELISA was set up for the detection of IFN-(capture: 
clone MD-1, 4 g/ml; detection: clone 4S.B3, 1 g/ml) IL-13 (capture: clone PVM13-1, 81
2 g/ml; detection: clone polyclonal, 1 g/ml) and IL-17A (capture: clone 
eBio64CAP17, 1 g/ml; detection: eBio64DEC17, 1 g/ml)  as described above. 82
Figure 2.1: ELISA standard curves.83
2.8. Quantitative real-time PCR
Taqman qPCR was used for the detection and quantification of IFN-gene expression. 
Total RNA was isolated using RNeasy Mini Kits (Qiagen) from MDDC or MDLC 
activated with LPS (100 ng/ml), poly I:C (50 g/ml), or infected with HSV (MOI 1), or 
cells co-cultured with Cos-7 cells expressing gBgD/gHgL, or mock transfected. First 
strand cDNA was synthesized from the purified RNA using the first strand cDNA 
synthesis kit according to manufacturer’s instructions (New England Biolabs). The 
following primers and probe were used for the detection of IFN-: 5’-
GAGCTACAACTTGCTTGGATTCC, 3’-CGTTAACTTACCCTCCGAAC and probe 
5’-ACAAAGAAGCAGCAATTTTCAGTGTCAGAAGCT with 5’ 6FAM fluorescent 
dye and 3’ BHQ1 quencher.  For each sample, the quantitative results were normalized 
to the quantitative levels of the “housekeeping” glyceraldehyde phosphate 
dehydrogenase (GAPDH) mRNA using the primers: 5’-
GGCTGAGAACGGGAAGCTT, 3’-AAGGTCCTCGCTCTAGGGA and probe 5’-
TCATCAATGGAAATCCCATCACCA. For all reactions, the cDNA were first 
denatured for 5 minutes at 95°C and then subjected to 50 cycles of PCR amplification of 
15 seconds at 95°C, followed by 50 seconds at 60°C. Real time PCR amplification was 
quantified with the ABI Prism 7000 System (PE Applied Biosystems). 
2.9. Microscopy
All confocal images were obtained with a Leica SP2 confocal microscope (Leica 
Confocal microscope) with a pin hole of 1 Airy (114.5 μm), scan speed of 400 Hz and 4 
frame averaging. The images were analyzed using the Leica Confocal software. 84
2.9.1. Confocal microscopy – cell surface staining
For cell surface staining for confocal microscopy, cells cultured on glass coverslips 
were harvested 18-24 hours post-stimulation and fixed with 3.7% paraformaldehyde for 
15 minutes prior to incubation with antibodies. Non-specific antibody binding was 
blocked with 10% goat serum (30 mins, RT).  Cells were stained for specific surface 
markers by incubation first with the relevant mAb (1 hour, RT) followed by 1:100 
diluted secondary conjugate goat anti-mouse Ig (Dako) (1 hour, RT). Cells were washed 
and stained with the DNA stain 4',6-diamidino-2-phenylindole (DAPI) (2g/ml) for 5 
minutes and mounted on slides. Samples were stored at 4°C in the dark until analysis. 
2.9.2. Confocal microscopy – intracellular staining
For intracellular staining for confocal microscopy, cells cultured on glass coverslips 
were harvested 1-6 hours post-stimulation and fixed with 3.7% paraformaldehyde. After 
washing off the fixative, cells were permeablized with TBS containing 0.2% Triton X-
100 (Sigma-Aldrich) for 10 minutes, non-specific antibody binding was blocked with 
10% goat serum, and the cells stained by overnight incubation (4º C) with primary 
antibody. Cells were then washed and stained with secondary conjugated goat anti-
rabbit Ig and nuclear counterstaining was performed with the DNA stain DAPI (2g/ml) 
and mounted on slides. Samples were stored at 4°C in the dark until analysis. Image 
analysis was performed with Metamorph v7.17 (Molecular Devices) to quantify 
nuclear: cytoplasmic ratios. 
2.9.3. Electron microscopy
For electron microscopy, all cells were grown on 6mm Thermonox coverslips and fixed 
in glutaraldehyde at 4º C, overnight. 85
Scanning EM
Coverslips were washed in PBS before fixed with osmium tetroxide solution for 30 
minutes. Coverslips were then washed in dH2O and dehydrated through graded acetone 
30%, 50%, 70%, 90% and 100%. Tetramethylsilane was then added, and the coverslips 
were air-dried. SEM images obtained using Philips 501 with Orion digital camera 
attachment.
Transmission EM
Coverslips were cut into strips, placed in screw cap and washed in dH2O. Coverslips 
were then fixed in osmium tetroxide solution to preserve phospholipoproteins, washed 
and dehydrated through graded alcohols 30%, 50%, 70%, 90% and 100%. Cells were 
then infiltrated with 1:1 resin:alcohol mixture, followed by 100% resin infiltration and 
embedded in labelled embedding moulds. Resin was removed from the non-cell side of 
coverslips and plastic was stripped from the cells. The resin containing cells was cut 
into semi-thin and ultra-thin sections using a Reichert Ultracut E. TEM images obtained 
using Philips CM120 (FEI) with AMT 2k digital camera attached. 
2.10. Analysis of TLR activation
Engineered HEK293 cells stabely transfected with a plasmid that constitutively 
expresses a single human TLR gene (Invivogen and gift of N. Witt) were used to test for 
viral triggering of the TLRs. Cells were grown in complete DMEM supplemented with 
100 g/ml Normocin and 10mg/ml Blasticidin or 10mg/ml Puromycin. At 80% 
confluency, cells were removed and seeded at 5x104 cells / well in a 96 well plate. Cells 
were stimulated for overnight incubation (37º C, 5% CO2) and the supernatant analyzed 
for IL-8 production. 86
2.11. Statistical analysis
Where appropriate, the means of paired groups were statistically analyzed using a 2-
tailed Student’s t-test or the one-way Anova test. 87
List of antibodies
Antibody Clone Source
CD1a NA1/34 (supernatant) Gift of A. McMichael
CD2 RPA-2.10 (purified) eBioscience
CD3 UCHT1 (supernatant) Gift of P.C.L. Beverley
CD14 HB246 (supernatant) Gift of P.C.L. Beverley
CD19 BU12 (supernatant) Gift of D. Hardie
CD40 5C3 (purified) eBioscience
CD80 2D10.4 (purified) eBioscience
CD83 HB15e (purified) eBioscience
CD86 BU63 (supernatant) Gift of D. Hardie
HLA-DR L243 (supernatant) Gift of P.C.L. Beverley
Mouse IgG1 Culture supernatant Dako
Mouse IgG2a Culture supernatant Dako
CCR7 150503 (purified) R&D Systems
E-cadherin 67A4 (purified) Santa Cruz 
Biotechnology
NF-kB p65 C-20 (purified) Santa Cruz 
Biotechnology
IRF3 FL-425 (purified) Santa Cruz 
Biotechnology
IRF7 H-246 (purified) Santa Cruz 
Biotechnology
HVEM Rabbit antiserum Gift of P. Spear
Nectin-1 CK-41 (purified) Gift of C. Krummenacher
Table 2.1: Non-conjugated antibodies to human antigens88
Antibody Clone Source
CD13-APC WM15 BD Bioscience
CD13-PE WM15 BD Bioscience
CD209 (DC-SIGN)-PE DCN46 BD Bioscience
CD303 (BDCA-2)-APC AC144 Miltenyi Biotec
p-NF-kB p65 (pS529) K10-895.12.50 BD Bioscience
Table 2.2: Conjugated antibodies to human antigens 89
Glycoprotein Backbone Source
gBgD pcDNA3.1 Gift of A. Minson
gHgL pcDNA3.1 Gift of A. Minson
gB (pSR175) pCMV3 Gift of G.H. Cohen and 
R.J. Eisenberg
gD (pDC390) pcDNA3.1 Gift of G.H. Cohen and 
R.J. Eisenberg
gH (pHC138) pCMV3 Gift of G.H. Cohen and 
R.J. Eisenberg
gL (pCMV3gL-1) pCMV3 Gift of G.H. Cohen and 
R.J. Eisenberg
gH Leu (L382P,GLL384-
386WPP)
pcDNA3.1 Gift of G. Campadelli-
Fiume
gH HR1-EL (E450G,L453A) pcDNA3.1 Gift of G. Campadelli-
Fiume
gH HR2-down2 (LARA570-
573AVPQ)
pcDNA3.1 Gift of G. Campadelli-
Fiume
gD- pDL485 (37C-302C) pcDNA3.1 Gift of G.H. Cohen and 
R.J. Eisenberg
gD- pDL449 (D30A) pcDNA3.1 Gift of G.H. Cohen and 
R.J. Eisenberg
gD- pDL490 (3C-38C) pcDNA3.1 Gift of G.H. Cohen and 
R.J. Eisenberg
Table 2.3: HSV-1 vectorsCHAPTER 3 - HSV-1 ENTRY GLYCOPROTEIN
MEDIATED MATURATION OF MDDC91
3.1. Introduction
Infection of DC by HSV-1 leads to a series of both morphological and functional 
changes which result in partial DC maturation, impairment of antigen presenting 
function and eventual apoptosis (Kruse et al., 2000; Pollara et al., 2003; Salio et al., 
1999). The relationship between viral attachment, fusion and entry, and the consequent 
signals which result in DC activation remain obscure. Inhibition of DC function is 
dependent on viral gene expression, since ultra violet (UV) light-inactivated virus, and 
mutants which do not express essential early transactivators, do not show these 
inhibitory effects (Pollara et al., 2003; Samady et al., 2003). In contrast, DC maturation 
is induced by UV treated or formaldehyde-inactivated HSV-1 particles (Pollara et al., 
2003). Hence, a role for the viral structural proteins in the activation of DC has been 
suggested. 
As outlined in chapter 1, four viral surface glycoproteins - gB, gD, gH and gL, are 
necessary for viral entry into cells. Significantly, these same four entry glycoproteins 
individually also play a key role in the interaction between HSV and the host immune 
system as they are important targets of adaptive immunity. However, their key role in 
initiating the early innate immune response to HSV is not well understood. 
Understanding the complex functions of these HSV proteins will facilitate in our 
understanding of HSV-1 pathogenesis, but also in the successful development of 
vaccines. 
3.2. Results
3.2.1. Monocyte-derived dendritic cell phenotype
MDDC were prepared as described in section 2.2.1. Consistent with the MDDC 
phenotype (Pickl et al., 1996), day 7 DC cultures were a homogenous population of 92
cells expressing high levels of CD1a and CD13 (fig. 3.1). To confirm the purity of the 
population, and absence of “contamination” from other non-DC PBMC, the cells were 
stained for the expression of CD3, CD14 and CD19 (T cells, monocytes and B cells 
respectively). As expected, the DC culture contained less than 1% CD19+ B 
lymphocytes or CD3+ T lymphocytes. These cells expressed low levels of CD14, 
consistent with the MDDC phenotype (fig. 3.1b). Fig 3.1c shows representative 
transmission and scanning EM images of DCs. The transmission image morphology 
shows a rounded mononuclear cell with a prominent nucleolus. The most striking 
feature are the numerous long processes which envelope the cell. These are relatively 
organelle free. There is little active secretory material and few lysosomes in the 
cytoplasm. The features resemble those of “veiled” cells. Scanning EM shows an 
elongated cell from which several dendritic processes are extended. In addition there are 
many surface fine processes. The features resemble those seen in our previous studies of 
these cells (Swetman CA et al., 2002).
One important characteristic of DC is the ability to transform from an immature state of 
antigen capture to a mature state of antigen presentation upon a signal from a pathogen 
– either by direct recognition, or indirect sensing of infection via soluble mediators. 
This transformation was confirmed phenotypically (fig. 3.2a) and morphologically (fig. 
3.2b). MDDC showed upregulation of surface markers CD40, CD83 and CD86, that are 
associated with this maturation, and of MHC class II (HLA-DR), upon stimulation with 
lipopolysaccahride (LPS). Thus both a) the immaturity state of day 7 cultured MDDC 
and b) their ability to acquire the surface phenotype of potent APCs was demonstrated 
clearly.93
3.2.2. MDDC susceptibility to HSV-1
As described previously, DCs are infected readily by HSV (fig. 3.3b). Using HSV/GFP 
as described previously, dose dependent infection could be monitored by measuring 
expression of GFP by flow cytometry (fig. 3.3a). Infection of DC at an increasing range 
of multiplicity of infection (MOI) resulted in overall high infection efficiency, and this 
increase was dose dependent.  94
Figure 3.1: Phenotype of immature DC. MDDC were prepared as described in 
Materials and Methods and analysed by flow cytometry. a) A representative FSC/SSC 
profile is shown in the left panel. Subsequent analysis is gated on the major live cell 
population shown as R1. R1 cells almost all expressed both the myeloid marker CD13 
and the MDDC marker CD1a.  b) R1 cells contained few B cells (stained with CD19) 
and express low levels of CD14. Filled profile shows staining with IgG control. c) 
Transmission and scanning EM of unstimulated MDDC.95
Figure 3.2: Maturation of MDDC. a) Representative example of MDDC stimulated 
with 100 ng/ml LPS showing upregulation of maturation markers CD86, CD83 and 
CD40, and also of HLA-DR. b) Morphological changes seen following MDDC 
maturation as captured by inverted phase contrast microscopy.96
Figure 3.3: HSV-1 infection of immature DC. a) Representative experiment showing 
MDDC infected with HSV-1/GFP at an MOI of 0, 1 and 5 pfu/cell, and GFP expression 
on the R1 population (panel a) as measured by flow cytometry 18 hrs post-infection. 
The percentage of positive cells (as compared to FL1 signal on uninfected cells, MOI of 
0) is indicated. b) Transmission EM of MDDC infected at an MOI of 1. Arrows 
indicating HSV/GFP. 97
3.2.3. Induction of MDDC maturation by HSV-1 glycoproteins
To investigate the interactions of the key HSV-1 surface glycoproteins with DC, 
independent of the effects of other virus components and viral infection, a model 
adapted from Turner et al. (Turner et al., 1998) was designed and developed, where 
Cos-7 fibroblasts were transfected to express the individual HSV-1 glycoproteins (gB, 
gD and the heterodimer gHgL). This strategy was designed to be less susceptible to LPS 
contamination than any strategy that was dependent on the use of purified 
glycoproteins, or of antibody inhibition, and allowed a much more flexible analysis of 
both glycoprotein combinations, and of mutant forms. Glycoprotein expression was 
monitored using antibodies specific for each respective glycoprotein, and examined 
either by flow cytometry (fig. 3.4a) or by confocal microscopy (fig. 3.4b). Optimum 
expression levels were observed 48 hours after transfection. Therefore Cos-7 cells that 
had been transfected for 48 hours were used to stimulate DC in subsequent experiments. 
Cos-7 cells expressing the four glycoproteins were frequently multinucleate, 
presumably as a result of cell-cell fusion induced by the glycoproteins (Turner et al., 
1998).
A dose response analysis was used to determine the optimum Cos-7 to DC ratio. 
Glycoprotein expressing Cos-7 cells were cultured in an increasing number (10
2 – 5x10
4
cells/well), co-cultured with a constant number of DC (3x10
5 cells/well) and then 
analyzed for maximum phenotypic DC response (fig. 3.4c). The data show a clear dose 
response with the optimum Cos-7 to DC ratio which gives the maximum DC response 
at 2.5 x 10
4 Cos-7 cells per 3 x 10
5 DC (ratio of approximately 1:10). This ratio was 
used thereafter in all subsequent experiments. 98
Day 7 DC were co-cultured with the TLR4 ligand, LPS, as a positive control for the 
induction of maturation; other controls were HSV/GFP (MOI of 5 pfu/cell giving an 
infection rate of around 80%); Cos-7 cells transfected previously with all four 
glycoproteins (gB, gD and gHgL); and mock transfected Cos-7 cells. After 18-24 hours 
of co-culture, all cells were collected and stained for CD13 to differentiate the MDDC 
from the Cos-7 cells, since CD13 (an aminopeptidase expressed exclusively on cells of 
myeloid origin) is a discriminatory marker that is not expressed on Cos-7 cells. CD13
+
MDDC cells were gated (fig 3.5) and the expression of maturation markers CD86, 
CD83 and HLA-DR were measured on these gated cells. Representative flow cytometry 
histograms from individual experiments (fig. 3.6a) and mean fluorescence levels 
obtained from several experiments (fig. 3.6b) are shown.
In agreement with previous studies, HSV-1 virions induced upregulation of all three 
surface markers, consistent with the induction of MDDC maturation, albeit the levels 
were statistically lower than those seen in the presence of LPS (fig. 3.6). However, Cos-
7 cells transfected with all four essential HSV-1 glycoproteins also induced strong 
upregulation of all three surface markers (fig. 3.6 bottom panels, compared to upper 
panel unstimulated; fig. 3.6). Levels of CD86 detected on MDDC co-cultured with 
transfected Cos-7 cell were similar to those on LPS-matured MDDC and higher than 
that obtained by stimulation with HSV/GFP. CD83 and HLA-DR expression on MDDC 
varies over a broader range after exposure to transfected Cos-7 and upregulation is 
mostly similar to that induced by HSV virions. Mock transfected cells did not mature 
MDDC significantly. Thus the four HSV-1 glycoproteins are sufficient to mature 
MDDC independent of any other viral components.99
In order to verify that DC maturation was the result of the glycoproteins and 
independent of the expressing cells (i.e. Cos-7 cells), CHO cells were also transfected 
with the HSV-1 surface glycoproteins, and co-cultured with immature DC. The CHO 
cells expressed similar levels of glycoproteins 48 hrs post-infection as the Cos-7 cells 
(data not shown). But, unlike the Cos-7 cells, these cells lack the HSV entry receptors 
and thus are non-permissive to HSV infections and to cell-cell fusion. Similar results of 
CD86 upregulation in DC were observed with all four glycoproteins compared to the 
Cos-7 cells (fig. 3.7). 100
Figure 3.4: Glycoprotein expression by Cos-7 cells. Cos-7 fibroblasts were 
transfected transiently with vectors expressing gB, gD, gH and gL, and cultured for 24, 
48 or 72h to allow expression of the glycoproteins at the cell surface. a) Expression of 
each glycoprotein was monitored by flow cytometry using Ab 2153 for gB, Ab LP2 for 
gD and Ab LP11 for gH/gL. A representative of three or more experiments is shown in 
each panel. b) Expression of glycoproteins following 48 hrs culture were monitored by 
confocal microscopy for expression of gD and gHgL. c) Glycoprotein expressing Cos-7 
cells were cultured in an increasing number, co-cultured with a constant number of DC 
and then analyzed by flow cytometry for maximum phenotypic CD86 DC response.101
Figure 3.5: Flow cytometric analysis of MDDC/Cos-7 cells co-cultures. a) Live cells 
present in DC/Cos-7 co-cultures were identified by gating on the FSC/SSC region R1 
and b) stained for CD13. Right peak represents the MDDC, left peak the Cos-7 cells. c) 
These cells were further divided into CD13
+ MDDC and CD13
- Cos-7 cells. The levels 
of maturation markers (as described in the text), were analysed on MDDC alone, by 
gating on the CD13
+ region R2.102
Figure 3.6: Cos-7 cells transfected with all four HSV-1 surface glycoproteins 
induce DC maturation. a) MDDC were cultured in medium (top row) or stimulated 
with either whole virus (HSV/GFP, MOI 5), LPS (100 ng/ml), or Cos-7 cells transfected 
with all four glycoproteins. The levels of CD83, CD86 and HLA-DR were measured by 
flow cytometry as in fig. 3.1c (for top three rows) or as described in fig. 3.4 for bottom 
row. Filled histograms show staining using an appropriate Ig control antibody. The 
vertical dotted line indicates the mode of the distribution in unstimulated immature 
MDDC. The figure shows one representative experiment from at least three independent 
experiments from three different donors. b) As in a, but figure shows the mean of the 
mean fluorescent intensity (MFI) values from three independent experiments. An 
additional group of MDDC co-cultured with mock transfected Cos-7 cells is included, 
but no significant differences were seen between mock transfected Cos-7 cells, 
untransfected Cos-7 cells, or MDDC alone. The experiments shown in left and right 
panels are shown separately since they were carried out using different batches of
secondary antibody, and hence the absolute values of fluorescence cannot be compared 
directly. Error bars represent standard error of the mean. Statistical analysis was 
performed using the Student’s t-test. * P < 0.05.   103
Figure 3.7: CHO cells transfected with all four HSV-1 surface glycoproteins induce 
DC maturation. MDDC were co-cultured with CHO cells transfected with all four 
HSV-1 glycoproteins, or with mock transfection, and the levels of CD86 were measured 
by flow cytometry. MFI values from two independent experiments from two different 
donors are shown. 104
3.2.4. All four HSV-1 surface glycoproteins are necessary for DC 
maturation
For viral cell entry in vitro (and possibly in vivo), all four HSV-1 glycoproteins (gB, gD 
and the heterodimer gHgL) are necessary as a complex. To test whether this is also true 
for the maturation of DC, we transfected Cos-7 cells with either one, two or three 
glycoproteins.  Because gL on its own is not present on the cell surface and because gH 
requires gL for cell surface expression (Hutchinson et al., 1992; Roop et al., 1993), 
gH/gL was transfected as a heterodimer only. Following DC co-culture, flow cytometry 
showed that neither gB/gD (3.8, third row), nor gH/gL (3.8, fourth row), nor gB or gD 
alone (not shown) induced significant upregulation of either CD86 or CD83.
Furthermore, DC formed distinct clusters around gB/gD/gH,gL transfected Cos-7 cells 
resembling the features noted in HSV-1 post – infection (Pollara et al., 2004a), while no 
clustering was observed when mock or three or less glycoproteins were transfected (fig. 
3.9). To confirm the requirement for all four glycoproteins in induction of DC 
maturation, glycoprotein-specific antibodies shown previously to inhibit HSV infection 
were added to the co-cultures. Antibodies to gHgL (LP11) and gD (AP7) inhibited DC 
maturation independently in the co-cultures (fig. 3.10). Antibody to gB (2153) did not 
block either DC activation or viral infection. 
Finally, soluble gD has recently been shown to induce cell signalling (Sciortino MT et 
al., 2008). Therefore, the ability of recombinant gD to induce DC maturation was tested. 
The recombinant soluble gD used to stimulate immature day 7 DC for this assay were 
gD285 and gD306 (both gifts of C. Krummenacher), both derived from HSV-1 KOS 
and known to bind to HVEM (Rux et al., 1998). These soluble glycoproteins were pre-
tested for traces of LPS contamination, using an E-Toxate Kit (Sigma) and gave a 105
positive result for the endotoxin (sensitivity of 2 pg/ml). However, despite this up to 25 
g/ml of recombinant gD was used to stimulate DC, and there was no maturation effect 
(as judged by flow cytometry) at any concentration tested (fig. 3.11). At 50 g/ml there 
was a slight shift, which could be due to the LPS contamination.  
3.2.5. Cell fusion is not the trigger for DC maturation
There are at least three diverse pathways used by HSV-1 in entry into different cell 
types that are susceptible to infection: via direct fusion with the plasma membrane, via 
fusion within an acidic endosome, and via fusion within a neutral endosome (Koyama 
AH and Uchida T, 1987; Nicola et al., 2003; Nicola et al., 2005; Milne et al., 2005). 
Since the complex of all four glycoproteins induces extensive cell fusion (Browne et al., 
2001) it was important to determine whether the fusion event per se was the trigger for 
induction of MDDC maturation. One way to block fusion is to fix the glycoproteins, 
thus blocking the conformational changes required. Previous studies have shown that 
HSV-1/GFP virions fixed in 0.05% glutaraldehyde still induced CD86 and CD83 
upregulation (Pollara et al., 2004a) (fig. 3.12a). The DC exposed to fixed HSV/GFP 
matured further in response to LPS, confirming their viability. Cos-7 cells transfected 
with all four glycoproteins, and then fixed in 0.05% glutaraldehyde, also induced DC 
maturation as efficiently as unfixed cells (fig. 3.12b). Thus fixation does not block the 
ability of the glycoproteins to induce DC maturation.
Various reports have suggested gHgL is one of the components required for viral fusion 
during HSV-1 entry , and the fusion domain within gH has been studied extensively 
(Forrester A et al., 1992; Gianni et al., 2005b; Gianni et al., 2005a). Therefore we 
confirmed that fusion was not necessary for the induction of DC maturation by HSV 
glycoproteins, by using gH mutants (see Materials and Methods) that lacked fusogenic 106
activity (Gianni et al., 2005b; Gianni et al., 2005a; Gianni et al., 2006). We transfected 
these mutants together with wild-type gB, gD and gL into Cos-7 cells. In the Cos-7 cells 
expressing all four wild-type glycoproteins, more than 90% of cells expressing gD were 
observed to be multinucleated, as a result of glycoprotein-induced Cos-7 cell fusion 
(fig. 3.13a, second panel). In contrast, Cos-7 cells transfected with gB, gD, gL and any 
of the mutant gH glycoproteins showed no evidence of multinucleate cells (fig. 3.13a, 
panel 3-5) confirming that these mutants were unable to induce cell fusion. However, 
Cos-7 cells transfected with the mutated gH were similar to wild type gH transfection in 
their ability to induce DC maturation (fig. 3.13b, CD83 data not shown). In agreement 
with the data obtained using fixed transfected Cos-7 cells, this data suggests that 
membrane fusion is not required for HSV-1 glycoprotein-induced MDDC activation.107
Figure 3.8: All four HSV-1 surface glycoproteins are necessary for phenotypic 
changes in DC. a) MDDC were co-cultured for twenty four hours with mock 
transfected Cos-7 fibroblasts, or Cos-7 cells transfected with either gBgDgHgL, gBgD 
only or gHgL only. Expression of CD86 and CD83 on CD13
+ MDDC was measured by 
flow cytometry as described in Legend to fig. 3.4 (white histogram). The grey 
histogram represents IgG control staining. The dotted line indicates the mode of the 
distribution in unstimulated immature MDDC. The figure shows one representative 
experiment from at least three independent experiments. b) As in a, but figure shows the 
MFI values from three independent experiments. Error bars represent the standard error 
of the mean. Statistical analysis was performed using the Student’s t-test. * P < 0.01. 108
Figure 3.9: All four HSV-1 surface glycoproteins are necessary for morphological 
changes in DC. Images of the cells in culture after twenty four hours were obtained by 
inverted phase contrast microscopy, showing clustering of DC on Cos-7 cells 
expressing all four glycoproteins. Filled arrows indicate MDDC, dashed arrows indicate 
Cos-7 cells.109
Figure 3.10: Anti-glycoprotein antibodies inhibit MDDC maturation. MDDC were 
co-cultured for twenty four hours with Cos-7 cells transfected with gBgDgHgL, and 
anti-gD (AP7) or anti-gHgL (LP11) specific antibodies or IgG2a control antibodies. The 
antibodies were added to the Cos-7 cells 1 hour prior to the addition of MDDC. CD86 
was measured by flow cytometry (white histograms). Grey histogram represents IgG 
staining control. Results are representative of three or more independent experiments. 
Lower histogram show MFI values relative to MFI of MDDC co-cultured with all four 
glycoproteins from three independent experiments. Error bars represent standard error 
of the mean. Statistical analysis was performed using the Student’s t-test. * P < 0.05.110
Figure 3.11: Soluble gD does not induce MDDC maturation. MDDC were 
stimulated with increasing concentrations of soluble gD (12.5 g/ml and 25 g/ml) or 
LPS (100 ng/, dotted histogram). Expression of CD86 was measured by flow cytometry. 
Grey histogram represents immature unstimulated MDDC.111
Figure 3.12: Glutaraldehyde fixation inactivates HSV-1, but does not block 
glycoprotein mediated MDDC maturation. a) MDDC were cultured with LPS (100 
ng/ml), viable HSV/GFP (MOI 5), 0.05% glutaraldehyde fixed HSV/GFP, or both LPS 
and fixed HSV/GFP. Expression of CD86 was analysed after 18 hours (white 
histograms). The inserted histograms show GFP expression to confirm that the 
HSV/GFP has been inactivated by the concentration of glutaraldehyde used in these 
experiments. b) Immature DC were co-cultured with mock transfected Cos-7 cells, 
viable Cos-7 cells transfected with all four glycoproteins , Cos-7 cells transfected with 
all four glycoproteins and then fixed with 0.05% glutaraldehyde, and fixed transfected 
Cos-7 cells and LPS (100 ng/ml). Expression of CD86 was analysed after 18 hours co-
culture (white). Grey histogram represents isotype control for staining.  Figures show 
one representative of three experiments. Bottom figure shows the MFI values relative to 
MFI of MDDC co-cultured with all four glycoproteins from three independent 
experiments. Error bars represent standard error of the mean. Statistical analysis was 
performed using the Student’s t-test. * P < 0.01, ** P < 0.05.    112
Figure 3.13: gH mutants lacking fusogenic activity do not induce DC maturation.
Control transfected Cos-7 cells (gBgD/gL) , or Cos-7 cells transfected with gBgDgHgL, 
or wild type gB, gD, gL together with mutants of gH, were cultured for 48 hours and 
stained for gD (to identify transfected cells) and DAPI (to identify nuclei). Presence of 
multinucleated cells was detected by confocal microscopy. The figures show a high 
magnification view of a single field; examination of multiple high power fields showed 
similar findings. b) Expression of CD86 on CD13
+ DC was measured by flow 
cytometry in MDDC co-cultured with Cos-7 cells transfected with either all four wild 
type glycoproteins gBgDgHgL, or with wild type gBgDgL and mutant gH (white 
histogram). The grey histogram represents immature MDDC. The vertical dotted lines 
represent the levels of these markers in mature DC. The figure shows one representative 
experiment from at least three independent experiments. Bar chart shows the MFI 
values relative to MFI of MDDC co-cultured with all four glycoproteins from three 
independent experiments. Error bars represent standard error of the mean. Statistical 
analysis was performed using the Student’s t-test. * P < 0.01, ** P < 0.1.   113
3.2.6. The DC response to HSV-1 glycoproteins is independent of the 
known HSV-1 receptors
HSV-1 interaction with susceptible cells is thought to occur via the interaction of the 
surface glycoproteins with one of several potential receptors. Currently HVEM and 
nectin-1 are the two receptors known to be expressed on DC that may interact with gD. 
More recently an integrin co-receptor, PILRalpha, has also been implicated, associating 
with gB during entry. These glycoprotein/receptor interactions are known to be 
necessary for entry; it is also possible that the interaction transduces activation 
pathways necessary for maturation. To test this latter possibility three gD mutants were 
used, one of which cannot bind HVEM [gD(D30A)], one of which cannot bind to 
nectin-1 [gD(A3C,Y38C)] and one of which binds neither receptor [gD(V37C-A302C)] 
(Krummenacher et al., 2005; Connolly et al., 2003; Connolly et al., 2005). Remarkably, 
all three mutants induced MDDC maturation when expressed together with gB and 
gH/gL, although levels of CD86 were consistently lower than those observed with wild 
type gD (fig. 3.14).
There are at least two known TLR pathways associated with HSV-1 infections although 
the ligand of the receptor on the virion has not been identified. One pathway involves 
detection via TLR-9 and is used by pDC to recognize HSV-1 and HSV-2 (Lund et al., 
2003; Krug et al., 2004); the other involves TLR-2 (Sato et al., 2006). In order to test if 
the glycoprotein-induced DC activation described thus far is mediated via these two 
pathways a HEK-293 cell line expressing the specific individual TLR was used. Upon 
triggering via the TLR these cells secrete IL-8 which can be detected by ELISA. As 
shown in figure 3.15, TLR-2 ligand Pam3Cys and TLR-9 ligand CpG were both 
powerful activators of IL-8 secretion in this system. In contrast, Cos-7 cells expressing 114
all four glycoproteins, similar to mock transfection failed to stimulate any significant 
IL-8 secretion.
To confirm the finding that the glycoprotein induced maturation was independent of 
TLR-2 and TLR-9, Cos-7 cells expressing the four entry glycoproteins were co-cultured 
with monocyte-derived Langerhans cells (MDLC) which have been shown previously 
to express no or very low levels of TLR-2 (Takeuchi et al., 2003; van der Aar et al., 
2007) and plasmacytoid DC (pDC) in which HSV-1 has been shown to trigger TLR-9 
(Lund et al., 2003). These results will be shown and discussed in chapter 5.  115
Figure 3.14: DC maturation response to viral glycoproteins does not require 
binding to HVEM and/or nectin-1. MDDC were co-cultured for twenty fours hours 
with Cos-7 cells transfected with either all four wild type glycoproteins gBgDgHgL, or 
with wild type gBgHgL and mutant gD as shown. Expression of CD86 and HLA-DR on 
CD13
+ DC was measured by flow cytometry (white histogram). The grey histogram 
represents IgG control staining. The vertical dotted lines represent the mode of the 
distribution for immature (left line) and LPS matured (right line) MDDC. The figure 
shows one representative experiment from at least three independent experiments from 
three different donors. 116
Figure 3.15: DC response to HSV-1 glycoproteins is independent of TLR-2 and 
TLR-9. HEK-293 cells stably expressing TLR-2 or TLR-9 were stimulated with TLR 
ligand (Pam3Cys for TLR-2; CpG for TLR-9) or were co-cultured with Cos-7 cells 
expressing either all four HSV-1 entry glycoproteins (gBgD/gHgL) or mock 
transfection. After an overnight co-culture, cells were analyzed for secreted IL-8 on an 
ELISA plate reader at 450 nm. Histograms represent the mean value of triplicate 
readings. The figure is one representative experiment from two independent 
experiments. 117
3.3. Discussion 
It has been shown previously that both UV inactivated virus and formaldehyde fixed 
virus (which are unable to express any de novo viral gene products) are still able to 
induce DC to mature, and this is reflected in resultant increase in T cells activation 
(Pollara et al., 2004a). This suggested that activation is mediated by components of the 
viral particle itself. The viral particle, however, contains many components which could 
in principal mediate DC activation. Therefore the first hypothesis tested in this study 
was whether or not the four entry glycoproteins, gB, gD, gH and gL, that are known to 
be involved in entry and membrane fusion, function as inducers of maturation in  DC.
In order to establish this role of HSV glycoproteins in the absence of other viral 
components we have adapted a model developed initially for the study of glycoprotein-
mediated attachment and fusion (Browne et al., 2001). In this model, DC are stimulated 
by Cos-7 cells expressing HSV-1 glycoproteins on their surface as a surrogate for 
exposure to intact viral particles. This strategy has proved robust, much less susceptible 
to LPS contamination than is seen when using purified recombinant glycoproteins, and 
allows a very flexible structure/function analysis of the role of individual glycoproteins 
and their combinations. This model system was then used to show clearly that the four 
entry glycoproteins were able to induce DC phenotypic maturation without requirement 
for any other viral component. This recognition pathway may be important in vivo, 
since glycoproteins are expressed at high levels on infected keratinocytes within HSV 
lesions (Cunningham AL et al., 1985). In a preliminary study looking at a keratinocyte 
cell line, HaCaT cells demonstrated a high susceptibility to HSV-1 infection and surface 
expression of the viral glycoproteins within a 24 hour infection (Appendix A).  
Interaction between DC and infected keratinocytes may provide one important signal 
for the initiation of adaptive immunity. 118
In principle the complex of four glycoproteins on Cos-7 cells is sufficient to allow 
fusion between Cos cells and DC (Reske A et al., 2007). Fusion in itself could provide a 
trigger for DC maturation, for example by introducing Cos cell DNA into the DC 
cytoplasm (Takaoka et al., 2007) rather than via the interaction between individual 
glycoproteins and their receptors. Two sets of experiments were carried out to test this 
hypothesis. In the first set, the transfected Cos-7 cells were fixed briefly with 
gluteraldehyde, which completely blocks fusion, before co-culture with the DC. In the 
second, a set of gH mutants with non-functional fusion domains was used (Gianni et al., 
2005b; Gianni et al., 2005a; Gianni et al., 2006). Both sets of experiments demonstrated 
unequivocally that DC maturation induced by the glycoproteins is independent of 
membrane fusion.
DC recognition of HSV-1 can therefore occur in the absence of other viral components, 
and in the absence of fusion. These results suggested strongly that a receptor (or 
receptors) is present on the DC surface, which is able to interact with the glycoproteins, 
and transmit an activating signal to the DC. Several receptors of the individual HSV-1 
glycoproteins have been described already (Spear, 2004; Satoh et al., 2008), with 
different distribution on different cell types. Thus we tested whether any of the 
glycoproteins individually could induce DC maturation via interaction with their 
respective receptors. Unexpectedly, DC maturation was found to require the co-
operative interaction of all four glycoproteins. The requirement for co-operative 
interactions was demonstrated both by transfection of each glycoprotein alone, or in 
various combinations, and also by the use of blocking antibodies to gD and gH. Both 
approaches confirmed the synergism between gB, gD and gH in triggering DC 
maturation.119
Of the known gD receptors, HVEM, a TNF receptor family member, signals via NF-B 
in response to its natural ligand LIGHT (Marsters et al., 1997; Tamada et al., 2000; 
Hikichi et al., 2001). Signalling via this receptor might therefore be an essential, though 
clearly not a sufficient event for the DC maturation that was seen in our Cos-7 model. In 
order to test this hypothesis a set of three gD mutants were used, which are unable to 
bind to HVEM, nectin-1 or either receptor respectively. All three mutants induced DC 
activation when used in conjunction with the other glycoproteins, albeit to a slightly 
lesser extent than the wild type protein. Thus the direct interaction between gD and 
HVEM or nectin-1 on the DC surface does not appear to be essential or sufficient for 
initiating DC maturation. It should be noted, however, that in receptor studies, one 
cannot rule out the possibility that in the absence of one receptor, gD binds to the other 
receptor, or to a totally different receptorthat has not as yet been identified. 
Finaly, the role of TLR-2 and TLR-9 in glycoprotein recognition was also excluded. 
These receptors have a well established role in innate responses to HSV-1 (Lund et al., 
2003; Krug et al., 2004; Sato et al., 2006);  however in this study their direct interaction 
with the four viral glycoproteins tested is not essential.  
3.4. Conclusion
In this chapter a method developed for the study of HSV-1 entry was used to unravel 
and understand the interactions between viral surface glycoproteins and MDDC. The 
results demonstrate, using a variety of different experimental approaches that in HSV-1 
maturation of DC all four known entry glycoproteins are necessary and sufficient and 
that this maturation is independent of the known HSV-1 receptors. This suggests that 
the initial interaction between the glycoproteins and DC is the trigger for maturation, is 
not dependent upon any other viral components.  120
This model and the results described will be used in the following chapters to further 
understand the interactions between the viral glycoproteins and DC. CHAPTER 4 – THE BIOLOGICAL CONSEQUENCE OF 
MDDC INTERACTION WITH THE HSV-1 
GLYCOPROTEINS122
4.1. Introduction
DC are the most potent antigen presenting cells, highly efficient at migrating to the 
lymph nodes to initiate primary T-cell mediated immune responses and also 
contributing to the release of pro-inflammatory cytokines and chemokines necessary for 
control of initial infection before adaptive immunity is operative. 
The role of these cytokines and chemokines as key effector molecules in all innate 
immune responses (whether triggered by viruses, or by other forms of injury) has been 
studied intensively in recent years, based upon new ideas about the significance of this 
phase of the reaction. With respect to HSV-1, the release of type I interferons (IFN) is 
an important component of the innate immune response to HSV-1 (Leib et al., 1999; 
Noisakran et al., 2000) and genetic defects in type I IFN production have been shown to 
increase susceptibility to HSV-1 encephalitis (Noisakran et al., 2000). Several 
pathways, both TLR-dependent and TLR-independent pathways have been described 
which lead to the production of type I IFN in innate immune cells as a consequence of 
viral infections. In these pathways, the nuclear factor B (NF-B) and the interferon-
regulatory factors (IRFs) have been shown to be important in regulation of type I IFN at 
the molecular level.
4.1.1. NF-B
NF-B is a key regulatory component in the control of both innate and adaptive 
immunity (Li and Verma, 2002). There are several subunits of NF-B and several 
pathways leading to activation. In the classical (canonical) pathway, RelA/p65 is bound 
initially to IB in an inactive form. Following activation, IB proteins are 
phosphorylated by IB kinases (IKK), ubiquitinated and eventually degraded allowing 123
the now unbound NF-B protein to translocate to the nucleus to be subsequently 
phosphorylated in order to regulate the transcription of a variety of genes. Two 
pathways have been described for the activation of IB degradation: a MyD88-
dependent pathway that promotes an immediate NF-B activation and induction of pro-
inflammatory cytokines; and a MyD88-independent pathway which mediates a late 
activation of NF-B and the induction of IFN genes and co-stimulatory molecules 
(Kawai et al., 1999; Kaisho and Akira, 2001; Kawai et al., 2001; Kaisho et al., 2001; 
Moynagh, 2005). Both TLR3 and TLR4 have been shown to use the MyD88-
independent NF-B activation pathway in the induction of type I IFN, specifically 
IFNand this involves phosphorylation of IRF3 (see below), which then co-operates 
with other transcription factors (Kawai et al., 2001; Doyle S et al., 2007). TLR7/8 and 
TLR9, which use the MyD88-dependent pathway, induce type I IFN via IRF7.     
4.1.2. IRF 
The mammalian IRF family consists of nine members, IRF1-9 (Taniguchi T et al., 
2001; Lohoff M and Mark TW, 2005). Of these, IRF3 and IRF7 have received most 
attention as the main regulatory factors for viral induced type I IFN (Yoneyama M et 
al., 1998; Sato et al., 1998b; Sato et al., 1998a; Marie I et al., 1998). Both proteins are 
found in the cytosol. IRF3 is expressed constitutively, whereas IRF7 is found in small 
amounts and is induced in an autocrine fashion by type I IFN-mediated signalling.  
Following viral infection, these proteins are phosphorylated and translocate to the 
nucleus to interact with the type I IFN genes. IRF3 is a potent activator of IFNB genes, 
but not IFNA genes, except for IFNA4. IRF7 activates both IFNA and IFNB genes 
efficeintly (Sato et al., 1998a; Marie I et al., 1998; Sato et al., 2000). Studies on IRF7 
knock-out mice (Honda et al., 2005) suggested a positive-loop model in which the small 124
amounts of IRF7 in the cytosol are responsible, as homodimers or heterodimer with 
IRF3, for the initial induction of IFN, whose binding to the IFN receptor (IFNR) 
brings about an upregulation of more cellular IRF7 which is responsible for the late 
phase and continuous production of the type I IFN (fig. 4.1).
Both the TLR-dependent (TLR3, TLR4, TLR7/8 and TLR9) and the TLR-independent 
(RIG-I and MDA-5) forms have been identified as inducers of type I IFN genes via the 
IRF3 and IRF7 pathways in response to viral infections (Honda et al., 2006; Honda and 
Taniguchi, 2006).
In chapter 3, the four viral entry glycoproteins were shown to be essential and sufficient 
to induce phenotypic maturation of MDDC. This chapter will study the biological 
consequences of the interaction between the four viral entry glycoproteins and MDDC, 
looking at the ability to activate T cells, cytokine production and the distinct signaling 
pathways that follow this interaction.125
Figure 4.1: Schematic diagram of IRF3/7 positive-loop regulation of type I IFN. In 
the early phase of infection, both IRF3 and IRF7 are phosphorylated resulting in either 
homodimerization of IRF7 or heterodimerization of IRF3 and IRF7. These dimers then 
translocate to the nucleus where they induce the production of small amounts of IFN
and IFN from the ifnb and ifna genes, respectively. Secreted type I IFN can then bind 
with the IFNR in an autocrine or paracrine manner to induce the transcription of the irf7 
gene. The IRF7 produced returns to the cytosol to induce the production of large 
amounts of type I IFN. 126
4.2. Results
4.2.1. MDDC exposed to the four viral entry glycoproteins do not induce 
enhanced T cell proliferation
Having shown that the four HSV-1 glycoproteins are able to up-regulate DC maturation 
markers, the comparative ability of these mature MDDC to induce allogeneic T cell 
proliferation was measured in a T cell proliferation assay. Similar to previous studies 
(Pollara et al., 2003), HSV-1 virions impaired the DC ability to induce T cell 
proliferation. In contrast to LPS stimulated MDDC which induced a significant increase 
in T cell proliferation compared to untreated controls, MDDC matured in the presence 
of Cos-7 cells expressing the HSV-1 glycoproteins were similar to unstimulated and 
mock transfected MDDC, with no increased T cell stimulating capacity (fig. 4.2a). 
Similar results were seen when the MDDC were stained for CCR7, a G protein-coupled 
chemokine receptor expressed on naïve T and B cells and mature/activated DC, and 
shown to control the migration of mature DC to lymph nodes (Dieu MC et al., 1998; 
Sallusto F et al., 1998). Unstimulated MDDC, HSV-1 infected MDDC and MDDC co-
cultured with transfected Cos-7 cells did not show an upregulation of CCR7 expression. 
The positive control, CD40L induced upregulation of CCR7 on MDDC as expected 
(fig. 4.2b).
Next the cytokines secreted by the MDDC responder T cells were measured. 
Supernatants were collected from the mixed MDDC-T cell allogeneic cultures 24 hours 
and 6 days post co-culture, and cytokine levels [IFN- (TH1), IL-13 (TH2) and IL-17A 
(Treg)] were measured by ELISA (fig. 4.3). At 24 hours, only MDDC that had been 
stimulated with LPS induced T cell IFN- synthesis. There was no IL-13 and no IL-17A 
release after 24 hours in any of the cultures. After 6 days in culture however, MDDC 127
stimulated with both LPS and poly I:C induced T cell release of  IFN- This was also 
seen with MDDC co-cultured with Cos-7 cells expressing the four viral entry 
glycoproteins (fig. 4.3a).  T cells co-cultured with MDDC matured by LPS, poly I:C, 
HSV-1 and the viral glycoproteins also produced low amounts of IL-13 (fig. 4.3b). IL-
17A cytokine was not detectable at either of the time points.128
Figure 4.2: DC matured by Cos-7 cells transfected with all four glycoproteins do 
not induce allogeneic T cell activation. a) MDDC co-cultured with Cos-7 cells 
expressing the four glycoproteins, mock transfected, or infected with HSV (MOI 1) 
were used to stimulate allogeneic T cell proliferation. MDDC activated with LPS (100 
ng/ml) and MDDC without any activation stimulus were used as controls. Results are 
expressed as mean counts per minute (cpm) of triplicate wells of T cells. Error bars 
represent standard error of the mean. Statistical analysis was performed using the 
Student’s t-test. * P < 0.05. A representative experiment from three independent 
experiments from three different donors is shown. b) Immature MDDC were co-
cultured with Cos-7 cells expressing four glycoproteins, mock transfection or infected 
with HSV, and stimulated with CD40L or unstimulated. CCR7 expression was 
measured by flow-cytometry 18 hrs post-stimulation. Dotted histograms represent the 
isotype control. A representative experiment from three independent experiments from 
three different donors shown.129
Figure 4.3: ELISA for T cell TH1 and TH2 cytokines. Supernatants from allogeneic T 
cells co-cultured with MDDC activated by LPS, poly I:C, HSV and Cos-7 cells 
transfected with all four glycoproteins were collected 24 hours and 6 days post-co-
culture. T cell secreted a) IFN- and b) IL-13 were determined by ELISA. All ELISA 
experiments were performed in duplicates. The figures show two representative 
experiments from two different donors from three independent experiments.130
4.2.2. HSV-1 surface glycoprotein interaction with MDDC induces release 
of type I IFN and IL-10 but no IL-12 or TNF-.
In HSV-1 infection, type I IFN produced early in the infection by different cell types 
blocks viral replication and is thus important in viral resistance (Mittnacht S et al., 
1988; Leib et al., 1999; Noisakran et al., 2000). Most cell types are able to secrete type I 
IFN. pDC, are known to secrete high levels of type I IFN in response to viruses, but 
with the appropriate stimulant myeloid DC can also induce secretion of large quantities 
of type I IFN, equivalent to that produced by pDC (Diebold SS et al., 2003). Therefore 
the type I IFN production was examined, monitoring secretion of IFN protein and 
synthesis of IFN mRNA. Supernatants from MDDC stimulated for 18 hours with poly 
I:C (50 g/ml), LPS (100 ng/ml), infected with HSV-1 or co-cultured with Cos-7 cell 
expressing all four entry glycoproteins were collected.  Fig 4.4a shows that MDDC co-
cultured with the four glycoproteins produced IFNα, as did MDDC co-cultured with 
whole virus, or with poly I:C. Co-culture with LPS did not result in release of IFNat 
this time point. Neither MDDC cultured with mock transfected Cos-7 cells, nor Cos-7 
cells alone, produced any detectable IFNα. 
Following five hour stimulation as described above, MDDC were harvested and cDNA 
synthesized from the extracted RNA. IFN mRNA was detected in MDDC stimulated 
with LPS (100 ng/ml), poly I:C (50 g/ml) and cells co-cultured with Cos-7 cells 
expressing the four glycoproteins (fig. 4.4b). No IFN was detected in unstimulated 
MDDC and only a minimal amount was detected in cells infected with HSV-1.
In contrast, neither HSV-1 virions nor the glycoproteins induced detectable IL-12p70 
(fig. 4.5a), although the MDDC were capable of releasing large amounts of this 131
cytokine under appropriate stimulation with LPS. Both MDDC co-cultured with the 
four glycoproteins and with whole virus produced small amounts of IL-10. MDDC 
exposed to mock transfected Cos-7 cells, or Cos-7 cells on their own did not produce 
detectable IL-10 (fig. 4.5b). Neither the MDDC co-cultured with Cos-7 cells transfected 
with the four glycoproteins nor the MDDC exposed to HSV-1 virions produced 
significant levels of TNF-(fig. 4.5c). 
4.2.3. IRF7, but not IRF3 is translocated to the nucleus in MDDC in 
response to HSV-1 and the viral glycoproteins
To investigate the role of the IRF3 and IRF7 pathway in the induction of type I IFN in 
MDDC, cells were stimulated with different TLR ligands, infected with HSV-1 or co-
cultured with transfected Cos-7 cells and the early (5 hours post-stimulation) nuclear 
translocation of IRF3 and IRF7 was measured by confocal microscopy. MDDC 
stimulated with imiquimod (a TLR7 ligand), CL075 (a TLR8 ligand), infected with 
HSV-1 or co-cultured with Cos-7 cells expressing the four entry glycoproteins all 
showed a significant nuclear translocation of IRF7, compared to unstimulated MDDC, 
which showed a nuclear to cytoplasmic ratio of less then one (fig. 4.6a). In contrast, the 
stimulated MDDC did not show nuclear translocation of phosphorylated IRF3 (fig. 
4.6b). 
Activation of NF-B was also measured in both unstimulated and stimulated cells. 
MDDC stimulated with TNF-, LPS, infected with HSV-1, co-cultured with viral 
glycoprotein, or mock transfected Cos-7 cells were harvested 1 hour post-stimulation. 
The activation of NF-B was determined by measuring the level of intracellular 
phosphorylated NF-B (fig. 4.7). Intracellular flow cytometry showed that LPS and132
TNF- both stimulate the phosphorylation of NF-kB as early as one hour following 
stimulation, whereas virus infected and glycoprotein stimulated MDDC did not.  
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Figure 4.4: HSV-1 entry glycoproteins induce a type I IFN response.                       
a) MDDC were stimulated with poly I:C (50 g/ml), LPS (100 ng/ml), HSV infected 
cells and cells co-cultured with transfected Cos-7 cells. Supernatants were collected 18-
24 hours post-stimulation and IFN- secretion was determined by ELISA. All ELISA 
experiments were performed in duplicates. A representative experiment from three 
independent experiments from three different donors is shown. b) RNA was extracted 
from MDDC stimulated as in figure a and cDNA was synthesized as described in 
Materials and Methods. IFN- mRNA was measured using qPCR. Graph represents the 
ratio of IFN- fold increase to unstimulated all normalized to GAPDH. All qPCR were 
preformed in duplicates. The figure shows one representative experiment from three 
independent experiments from three different donors.134
Figure 4.5: ELISA for IL-12p70, IL-10 and TNF-. MDDC were stimulated with 
LPS(100 ng/ml), HSV infected or co-cultured with transfected Cos-7 cells. Supernatants 
were harvested 18-24 hours after stimulation and the cytokine secretion (IL-12p70, IL-
10 and TNF-) was determined by ELISA. All ELISA experiments were performed in 
duplicates. A representative experiment from at least three independent experiments is 
shown.135
Figure 4.6: MDDC induce the nuclear translocation of phosphorylated IRF7, but 
not IRF3. Stimulated MDDC were fixed and permeabilized five hours post-stimulation 
and the nuclear:cytoplasmic ratio of a) IRF7 and b) IRF3 was quantified. Data points 
represent mean from at least seven separate high power field images from three 
different donors. Error bars represent the 5% and 95% confidence intervals. Horizontal 
dotted lines represent the nuclear:cytoplasmic ratio of 1. Statistical analysis was 
preformed using the one-way Anova test. * P < 0.01.136
Figure 4.7: HSV-1 does not stimulate the early phosphorylation of NF-B RelA. 
MDDC stimulated with LPS (100 ng/ml), TNF-ng/ml), HSV-1 infected, Cos-7 
cells transfected with all four glycoproteins or mock transfected Cos-7 cells were fixed 
and permeabilized one hour post-stimulation. Phosphorylation of NF-kB RelA was 
measured by flow cytometry. a) Grey histograms represent the stimulated MDDC; open 
histograms represent the unstimulated MDDC. A representative example from three 
independent experiments from three different donors is shown. b) MFI showing the 
phosphorylated NF-kB relative to the native form. Data is from three independent 
experiments. Horizontal dotted line represents a NF-kB to unstimulated ratio of 1. Error 
bars represent the SEM. Statistical analysis was performed using the one-way Anova. * 
P < 0.05.137
4.3. Discussion
In the previous chapter the HSV-1 glycoproteins necessary for viral entry have been 
shown to induce phenotypic maturation in MDDC. In this chapter, however, data is 
presented which shows that these glycoproteins failed to enhance MDDC activation of 
allogeneic T cells, and did not induce expression of the chemokine receptor CCR7. This 
finding suggests that, similar to whole virus, the glycoproteins induce “partial 
maturation”, stimulating an innate antiviral response (i.e. type I interferon), but without 
enhancing T cell proliferation. Several examples of this type of partial maturation have 
been reported previously (Lutz and Schuler, 2002; Kleindienst et al., 2005; Verginis et 
al., 2005; Krathwohl et al., 2006; Braun et al., 2006; Bayry et al., 2007; Dulphy et al., 
2007). In certain cases partial maturation has been associated with the induction of 
tolerance or regulatory T cells (Kleindienst et al., 2005; Verginis et al., 2005). However, 
here studies on representative TH1 (IFN-), TH2 (IL-13) and TH17 (IL-17A) cytokines 
which could be secreted by the co-cultured T cells demonstrated that although the 
glycoprotein matured MDDC did produce a small amount of IL-13 (but no IL-17A), the 
main cytokine secreted was IFN-, implying a TH1 response. Interestingly, T cells co-
cultured with whole HSV-1 infected MDDC did not produce any IFN-. However, these 
T cells did produce minimal amount of IL-13, suggesting the virus skews the response 
towards a TH2 response compared to a TH1 response by the glycoproteins.     
One of the key features of DC is their ability to produce a type I IFN in response to viral 
infections (Reviewed in Fitzgerald-Bocarsly and Feng, 2007). Indeed type I IFNs are 
key effector molecules of the innate anti-HSV-1 immune response (Leib et al., 1999; 
Noisakran et al., 2000; Casrouge et al., 2006) and release of IFN induced maturation 
and viral resistance in neighbouring DC, which could mimic what happens in vivo  138
within and immediately around a zone of infection (Pollara et al., 2004b). Here the 
interaction of MDDC with glycoproteins and to a lesser extent infection by HSV-1, 
leads to the release of IFN18-24 hours post-stimulation. This release of IFN is 
independent of viral DNA, although the possibility cannot be excluded that Cos-7 cells 
nucleic acid engulfed by the DC play a role. 
With respect to IFNqPCR for mRNA, showed that the glycoproteins, and to a lesser 
extent the whole virus, induce early IFN mRNA upregulation and presumably release 
of IFNimmediately post-stimulation. 
Several signaling pathways have been described for the initial production of type I IFN. 
Using a direct nuclear translocation assay, this study shows that the initial pathway 
activated following HSV-1 and the glycoprotein stimulation of MDDC is mediated via 
IRF7.  Therefore, although the molecular pathway leading from glycoprotein 
recognition to DC response has not been characterised completely, the nature of this 
response suggests a model in which the glycoproteins initiate an initial IFN production 
upon interaction with DC; and this in turn upregulates the later and more long-lived 
production of IFNvia a positive feedforward loop. The low amount of detectable type 
I IFN stimulated by the whole virus, compared to the amount that the glycoproteins 
stimulated, may be attributed to one or more of several viral proteins known to be 
responsible for the evasion mechanisms (Mossman et al., 2000; Eidson et al., 2002; 
Harle et al., 2002; Melroe et al., 2004; Melroe et al., 2007).    
With regard to other cytokines, MDDC stimulated with HSV-1 glycoproteins also 
produced small amounts of the anti-inflammatory cytokine IL-10, but did not produce 
any detectable IL-12.  IL-12 is a key cytokine with an important role in the TH1 
response (Hsieh CS et al., 1993; Manetti R et al., 1993). However, recent studies 139
suggest that IL-12 is not an absolute requirement for the initial priming of cells towards 
TH1, but is important for the subsequent expansion of these cells (Noble A et al., 2001). 
A similar high IL-10:IL-12 ratio has been found in recurrent HSV lesions in vivo
(Mikloska Z et al., 1998). A previous study has reported IL-12 mRNA, but no IL-12 
protein production in HSV-1 infected blood DC (Ghanekar et al., 1996). The lack of IL-
12 response during HSV-1 infection can be attributed to the viral virion host shut off 
(vhs) protein which suppress the host’s cellular protein synthesis (Smiley, 2004). 
However, the lack of response to Cos-7 transfected cells cannot be attributed to this 
protein. Down-regulation of IL-12 may also be the result of autocrine IL10 feedback, 
since Cos-7 cells expressing the four glycoproteins do stimulate IL-10 release, and IL-
10 blocks transcription of both IL-12 subunit genes (D'Andrea A et al., 1993; Aste-
Amezaga et al., 1998). 
Neither the virus nor the viral glycoproteins induced any detectable immediate (one 
hour) NF-B phosphorylation. This finding correlates with the lack of pro-inflammatory 
cytokine production observed in these cells, as several studies have suggested that rapid 
NF-B phosphorylation is responsible for the induction of pro-inflammatory cytokine 
production (Kawai et al., 1999; Kaisho and Akira, 2001). Alternatively, this might be 
due to the sensitivity of the method applied, although phosphorylation could be detected 
in response to both LPS and TNF.
4.4. Conclusion
In this chapter the functional consequences of the interaction between the viral 
glycoproteins and MDDC have been analyzed. The results demonstrate clearly that the 
four HSV-1 entry glycoproteins do not enhance the proliferation of co-cultured T cells, 
although they do elicit a TH1 response. Furthermore, MDDC matured by the 140
glycoproteins produce a type I IFN necessary for an anti-viral response. This response 
was dependent on the initial IRF7 nuclear translocation.CHAPTER 5 - HSV-1 ENTRY GLYCOPROTEIN
INTERACTION WITH OTHER DC TYPES: LANGERHANS 
CELLS AND PLASMACYTOID DC142
5.1. Introduction
The skin acts as a first line of defence against infection. In addition to a barrier function, 
there are two major functional compartments which can be elicited rapidly: an innate 
immune response, involving the recognition of the pathogen, and expression of pro-
inflammatory cytokines and IFNs; and an “early warning” system, which attracts any 
adaptive immune response that has been primed previously (Meyer T et al., 2007).  
Two subsets of DCs are found constitutively within the non-infected normal human 
skin. These are epidermal LC, present in the suprabasal layer of the epidermis, in tight 
contact with keratinocytes via E-cadherin-mediated adhesion, and DDC found within 
the dermis. These cells capture antigen and release pro-inflammatory cytokines in a 
non-antigen specific fashion and are responsible for the recruitment of more cells to the 
site of infection, including peripheral pDC.
In natural HSV-1 infection, the virus spreads by direct contact, entering the mucous 
membrane or damaged skin of the host. It has been suggested that upon infection, the 
virus interacts with both the epidermal LC and DDC, although there is no direct 
evidence in humans that HSV-1 infects either of these cell types in vivo.
Having shown that the interaction between MDDC, which have a phenotype broadly 
comparable to that which has been ascribed to DDC (Grassi et al., 1998), and viral entry 
glycoproteins induces a more mature phenotype, and a type I IFN response, in this 
chapter the in vitro interaction between HSV-1 and other forms of potential cutaneous 
DC has been investigated.  143
5.2. Results
5.2.1. Monocyte-derived Langerhans cells phenotype
MDLC were prepared as described in section 2.2.2 by the addition of TGF- on day 0 
and day 4 of monocyte differentiation. Similar to MDDC as shown in figure 3.1, day 7 
MDLC cultures were a homogenous pure population of cells (data not shown). 
However, these cells were found to express E-cadherin, characteristic of LC (fig. 5.1a) 
and low levels of DC-SIGN while MDDC expressed high levels of DC-SIGN and little 
E-cadherin (fig. 5.1b).  
To characterize the the key functional properties of the MDLC population further, 
expression of the maturation marker CD86 in response to different TLR ligands was 
compared between MDDC and MDLC (fig. 5.1c). Pam3CSK4 (TLR2), poly I:C 
(TLR3), LPS (TLR4) and CL075 (TLR8) all induced significant upregulation of CD86 
in MDDC, whereas only poly I:C and CL075 induced a significant upregulation of 
CD86 in MDLC. Neither cell population showed a maturation phenotype in response to 
either imiquimod (TLR7) or CpG oligodeoxynucleotides (TLR9). This is consistent 
with the reported lack of TLR7 and TLR9 on myeloid derived DC ( Rozis et al., 2000; 
Takeuchi et al., 2003; van der Aar et al., 2007) and confirms that with respect to these 
two TLR, MDLC had the same phenotype as MDDC.144
Figure 5.1: Comparative charachterization of MDDC and MDLC. MDDC and 
MDLC were prepared as describe in Materials and Methods and analyzed by flow 
cytometry. Expression of a) e-cadherin and b) DC-SIGN was measured. Empty profile 
shows staining of MDDC, filled profile shows staining of MDLC. b) The mean 
fluorescent intensity (MFI) level was compared between the two subsets (a and b lower 
histograms). Error bars represent the standard error of the mean (SEM). Statistical 
analysis was preformed using the Student’s t-test. * P < 0.05. c) MDDC and MDLC 
were stimulated with different TLR ligands and the levels of CD86 were measured by 
flow cytometry. Graph represents the MFI relative to unstimulated cells. Error bars 
represent the SEM. Statistical analysis was preformed using the Student’s t-test for each 
TLR ligand used. * P < 0.05. All experiments were performed three or more times. 145
5.2.2. Induction of MDLC maturation in response to HSV glycoproteins
To investigate the interaction of HSV-1 and the viral glycoproteins with LC, MDLC 
were either infected with virus or co-cultured with Cos-7 cells expressing all four 
glycoproteins. Viral infection (measured by expression of the GFP transgene) and 
expression of maturation phenotype was measured by flow cytometry (fig. 5.2). At a 
MOI of 1 pfu per cell, 55% of the MDLC were GFP positive (fig. 5.2a), similar to the 
reported infection efficiencies in MDDC (fig. 3.3a). MDLC infected with the virus also 
showed a maturation phenotype with upregulation of the maturation marker CD86 (fig. 
5.2b).  
Similar to the results obtained with MDDC, in MDLC Cos-7 cells expressing all four 
entry glycoproteins also induced upregulation of CD86 following an 18-24 hour co-
culture. Mock transfected Cos-7 cells had no effect on CD86 expression (fig. 5.2b). 
However, CD83 and HLA-DR were only partially up-regulated in MDLC (fig. 5.2c). 
Thus, as with MDDC, HSV-1 is able to infect and induce phenotypic maturation of 
MDLC, and maturation requires only the four HSV-1 essential entry glycoproteins 
independent of any other viral components.
5.2.3. MDLC do not produce detectable type I IFN, IL-10, IL-12p70 or TNF
in response to maturation
The production of type I IFN by MDLC was also examined. MDLC were differentiated 
from the same donors as used for the measurement of MDDC cytokine production and 
stimulated with poly I:C (50 g/ml), LPS (100 ng/ml), infected with HSV-1 or co-
cultured with Cos-7 cell expressing all four entry glycoproteins. The supernatants were 
collected 18 hours post-stimulation. IFN production was determined by ELISA.  Only 146
poly I:C induced secretion of IFN in MDLC, although quantitatively less than that 
produced by MDDC (fig. 5.3a). Neither MDLCs infected with HSV-1 nor co-cultured 
with Cos-7 cells expressing the four glycoproteins produced any detectable IFN. 
The upregulation of IFN mRNA was also determined in these cells. Five hours post-
stimulation, RNA was extracted and cDNA synthesized as described in Materials and 
Methods. Compared to MDDC, where IFN mRNA was determined in the same 
reaction, MDLC did not upregulate any detectable IFN mRNA (fig. 5.3b). Together 
these data show MDLC exhibit significantly less capacity for antiviral type I IFN 
responses than MDDC.
Furthermore, MDLCs did not secrete IL-10 or IL-12p70 in response to either the virus 
or the viral glycoproteins, or in response to any of the TLR ligands tested. MDLC 
stimulated with Pam3CSK4, poly I:C and LPS did, however, produce TNF, although 
this was significantly lower than the amount induced by MDDC when stimulated with 
LPS (not shown). TNF was not detected in either MDLC infected with HSV-1 or 
stimulated with Cos-7 expressing the four viral glycoproteins. Thus, although HSV-1 
does infect MDLC, and MDLC responds to HSV-1 glycoproteins by upregulation of 
cell surface maturation markers, the MDLC did not respond in the same way as MDDC 
in terms of cytokine synthesis and release.   147
Figure 5.2: HSV-1 and Cos-7 cells expressing the four viral entry glycoproteins 
induce MDLC maturation. a) MDLC were infected with HSV-1/GFP MOI 1 and the 
percentage of cells expressing GFP was measured by flow cytometry. MDLC were 
infected with HSV-1/GFP or co-cultured with Cos-7 cells expressing the four viral entry 
glycoproteins and the level of b) CD86, c) CD83 and d) HLA-DR expression was 
measured. The small histograms represent HSV-1 infectivity as measured by GFP 
expression. The vertical dotted line indicates the mode of the distribution in 
unstimulated MDLC. All panels show one representative experiment from at least three 
independent experiments from three different donors. Right histograms show the 
relative MFI fold change from three independent experiments. Error bars represent 
standard error of the mean. Statistical analysis was performed using the one-way Anova 
test. * P < 0.05.148
Figure 5.3: MDLC stimulation does not induce the production of type I IFN. a) 
MDDC and MDLC were stimulated with poly I:C or LPS, HSV infected, or co-cultured 
with transfected Cos-7 cells. Supernatants were harvested 18-24 hours post- stimulation 
and IFN- secretion was determined by ELISA. All ELISA experiments were 
performed in duplicates. The figure shows one representative experiment from three 
independent experiments from three different donors. b) RNA was extracted from 
MDDC and MDLC stimulated as in figure a) and cDNA was synthesized as described 
in Materials and Methods. IFN- mRNA was measured using qPCR. Graph represents 
the ratio of IFN- fold increase to unstimulated, normalized to GAPDH. All qPCR were 
performed in duplicates. A representative experiment from three independent 
experiments from three different donors is shown.149
5.2.4. MDLC do not induce the activation of T cells
HSV-1 virions and the viral glycoproteins do not enhance the ability of MDDC to 
induce proliferation of allogeneic T cells (see 2.2.1), but this has not been examined 
previously using MDLC as APCs. Thus, the ability of MDLC to activate allogeneic T 
cells was measured. In general, MDLC were less efficient that MDDC at stimulating T 
cells proliferation (fig. 5.4). Even when stimulated with LPS or poly I:C (fig. 5.4 top 
right panel), MDLC-induced proliferation was still significantly less than the 
proliferation of the same donor’s T cells after co-culture with MDDC (fig. 5.4 top left 
panel).  
To consolidate these findings further, the cytokines secreted by the MDLC stimulated T 
cells (IFN-, IL-13 and IL-17A) were also measured by ELISA as described for MDDC. 
T cells co-cultured with MDLC did not produce detectable cytokines at 24 hours. After 
6 days of culture, the T cells co-cultured with poly I:C and viral glycoproteins 
stimulated MDLC also secreted IFN-, although the amount of this cytokine measured 
was close to the ELISA sensitivity threshold (fig. 2.1), and was less than that induced 
by T cells co-cultured with MDDC (p < 0.01) (fig. 5.5a). T cells co-cultured with 
MDLC matured by LPS, poly I:C and the viral glycoproteins also produced low 
amounts of IL-13. None of the MDLC stimulated T cells produced any IL-17A. 150
Figure 5.4: MDLC do not induce the activation of allogeneic T cells. MDDC and 
MDLC co-cultured with Cos-7 cells expressing the four glycoproteins, mock 
transfected, or infected with HSV-1, stimulated with LPS, poly I:C or unstimulated 
were used to stimulate allogeneic T cells proliferation. Figure shows the mean counts 
per minute (cpm) of triplicate wells of T cells in a DC dose response. Experiments from 
two different donors representative of three independent experiments from three 
different donors are shown.151
Figure 5.5: ELISA for T cell TH1 and TH2 cytokines. MDDC and MDLC were 
stimulated as described in figure 5.4 and cultured with allogeneic T cells. Supernatants 
were collected at 24 hours and 6 days post-co-culture. Secreted a) IFN- and b) IL-13 
were determined by ELISA. All ELISA experiments were performed in duplicates. 
Error bars represent standard error of the mean. All experiments were performed three 
times from three independent donors.152
5.2.5. HSV-1 glycoproteins do not induce maturation in peripheral 
plasmacytoid DC 
pDC are a distinct subtype of DC expressing TLR-9 with a potent ability to produce 
high levels of type I IFN in response to viral infection (Siegal et al., 1999; Asselin-
Paturel et al., 2001; Colonna et al., 2002). These cells are known to express CD303 and 
CD304 on their surface, and therefore these markers were used to isolate them from 
PBMC (fig. 5.6). 
HSV-1 virion induced upregulation of the maturation marker CD80 in pDC (fig. 5.7b). 
On these cells CD83 was not upregulated. Interestingly, only 4% of the gated cells (5% 
of total pDC) expressed GFP (fig. 5.7a). Neither the four glycoproteins, nor the single 
glycoproteins induced maturation (fig. 5.7c). 
Supernatants from pDC co-cultured with Cos-7 cells expressing the four glycoproteins, 
mock transfected Cos-7 cells, HSV-1 infected pDC and CpG stimulated pDC were used 
for the measurement of IFN and TNF-. In accordance with the flow cytometry 
results, both the CpG stimulated and the HSV-1 infected pDC produced both cytokines, 
while the pDC co-cultured with the mock transfected and the four glycoproteins 
transfected Cos-7 cells did not (fig. 5.8).  153
Figure 5.6: Peripheral plasmacytoid DC phenotype. pDC were isolated from PBMC 
by immunomagnetic cell sorting for CD304. They were examined for expression of 
CD303. A homogenous pure population of pDC is shown. 154
Figure 5.7: HSV-1 entry glycoproteins do not induce pDC maturation. a) pDC 
infected with HSV-1/GFP and the percentage of cells expressing GFP was measured by 
flow cytometry. b) pDC were infected with HSV-1 or stimulated with CpG (and the 
expression of CD80 and CD83 was measured by flow-cytometry. Empty histograms 
represent the unstimulated pDC. c) pDC were co-cultured with Cos-7 cells expressing 
the four HSV-1 entry glycoproteins or single glycoproteins and the expression of CD80 
and CD83 was measured. Empty histograms represent pDC co-cultured with mock 
transfected Cos-7 cells. A representative of two independent experiments from two 
different donors is shown. 155
Figure 5.8: HSV-1 entry glycoproteins do not induce pDC cytokine secretion. pDC 
were stimulated with CpG (5 g/ml), HSV-1 infected, co-cultured with Cos-7 
transfected with all four glycoproteins, Cos-7 cells transfected with single glycoproteins 
or Cos-7 cells mock transfected. Supernatants were collected 24 hours post-stimulation 
and TNF- and IFN- were measured by ELISA. All ELISA experiments were 
performed in duplicates. A representative experiment from at least two independent 
experiments is shown.156
5.3. Discussion 
The predominant site of HSV-1 primary infection is in the skin and mucosal surfaces. 
Therefore, in order to understand both immune defence against the virus, and associated 
immunopathology, it is important to identify and analyze the APCs that are found at 
these sites that might be implicated in the early responses to the virus. Therefore in this 
chapter the function of MDLC, as representative of epidermal LC, and of pDC, were 
studied in response to HSV-1 and the viral glycoproteins. 
Most previous functional studies on LC, as the prototype of skin DC, and their 
responses to pathogens such as HSV-1, have focused primarily on cells isolated from 
animal models (Geissmann et al., 1998; Nunez et al., 2004). This is due, at least partly, 
to the fact that direct ex-vivo isolation of LC from human skin is associated with 
significant spontaneous maturation, possibly due to the migration step that is used most 
often when isolating these cells from skin explants (Tchou et al., 2003). In a single 
preliminary study, we attempted to isolate epidermal LC directly from the skin by 
migration, but similar to Tchou’s studies, we found the “unstimulated” LC to be in a 
state of maturation (Appendix B). 
A modified MDLC protocol, which generates cells with distinguishing features that 
discriminate them from conventional MDDC, has been described (Geissmann et al., 
1998). Therefore, in this study we focused on these MDLC, and compared them with 
MDDC. 
Like LC, DDC are a probable site of early contact and response to HSV-1; and, like LC, 
ex vivo derived DDC are difficult to isolate and investigate. Thus in the first part of the 
study we were concerned not only with characterization of the MDLC, but also with 
confirming that the MDDC did resemble what is known about DDC phenotype, and 
about their core functions, as exemplified by responses to TLR ligands. The key 157
features which discriminate between the different DC forms are summarized in Table 
5.1. Both the cell surface phenotype (DC-SIGN
low and E-cadherin
high  for MDLC, DC-
SIGN
high and E-cadherin
low  for MDDC), and the functional TLR expression (TLR2
low, 
TLR3, TLR4
low and TLR8 for MDLC; TLR2, TLR3, TLR4 and TLR8 for MDDC) was 
consistent with that reported for LC and DDC respectively (van der Aar et al., 2007; 
Ebner et al., 2004; Teunissen, 2005; Flacher et al., 2006). Other studies have shown 
different TLR expression in blood-derived LC-like cells (Renn CN et al., 2006; Rozis G 
et al., 2008), but these LC-like cells were derived from CD34+ cord blood cells, and 
their TLR expression was different from that of ex-vivo epidermal LC.
Next we compared the two cell types with respect to their response to HSV-1, the four 
essential viral entry glycoproteins, gB, gD and the heterodimer gHgL. In previous 
studies (Pollara et al., 2003) and in the current work (chapter three and four) both HSV-
1 and the these glycoproteins expressed on the surface of transfected Cos-7 cells act as a 
novel PAMP, inducing maturation and partial activation of MDDC. In this study we 
extended these studies to show that MDLC also respond to HSV-1 and the 
glycoproteins, by upregulating surface markers expression, suggesting that these APCs 
are also capable of recognizing the HSV-1 surface. 
One of the key features of DC is their ability to produce a type I IFN response to viral 
infections (Fitzgerald-Bocarsly and Feng, 2007). Type I IFNs are key effector 
molecules of the innate anti-HSV-1 immune response (Leib et al., 1999; Noisakran et 
al., 2000; Casrouge et al., 2006). Here, compared to MDDC, which produce both IFN
and IFN in response to TLR stimulation, and to both the virus and the viral 
glycoproteins, MDLC do not show a type I response. 158
The comparative role of MDDC and MDLC in the activation of T cells was also 
examined. Our previous studies demonstrated that neither HSV-1 nor viral 
glycoproteins enhanced the ability of MDDC to stimulate T cell proliferation (section 
4.2.1), and indeed infection with HSV-1 was associated with a reduction in stimulating 
activity. A similar general pattern was now observed in MDLC, although in general 
MDLC were weaker activators of T cells than MDDC. 
Finally, the TH1 and TH2 cytokine (effector) responses of the T cells to MDDC and 
MDLC, with and without pre-stimulation were examined. Supernatants from T cells co-
cultured with stimulated DC cells were collected at 24 hours and 6 days to measure both 
immediate and late T cell cytokine secretion. MDLC were poor stimulators of IFN
even after stimulation, but responded to HSV glycoproteins by producing IL-13 in 
response to LPS, poly I:C and the glycoproteins. There was no response to HSV-1. 
The data presented in this chapter demonstrate differences between MDDC and MDLC 
in the response to HSV and the viral glycoproteins. Although MDLC can be infected by 
the virus and demonstrate a maturation phenotype in response to the viral glycoproteins, 
these cells are not activated by the virus or the glycoproteins. This is consistent with 
previous studies, particularly with HSV-2 in a mouse model, which suggested that LC 
have a less direct role in the immune response compared to the other DC forms (Allan 
et al., 2003; Zhao et al., 2003; Belz et al., 2004; Lemos et al., 2004). The present study 
provides useful confirmation that this is true for human immune responses to HSV-1. 
This question is discussed in more detail below in section 6.3. 159
MDDC MDLC LC 
1 DDC
  2
DC-SIGN high low low  high 
E-cadherin low high high  low 
TLR2 high low low  high 
TLR3 high high high  high 
TLR4 high low low  high 
TLR7 NE NE NE  low 
TLR8 high high Low high 
TLR9 NE NE NE  NE 
NE = not expressed
1 (Teunissen, 2005; Flacher et al., 2006; van der Aar et al., 2007)
2 (Teunissen, 2005; van der Aar et al., 2007)
Table 5.1: Characterization of MDDC and MDLC compared to ex-vivo LC and 
DDC. 160
With respect to pDC (Asselin-Paturel et al., 2001), which were also investigated here, 
high levels of IFN-and TNF- were detectable in pDC stimulated with CpG, a TLR-9 
ligand, and in pDC infected with the HSV-1 virions, although the percentage of pDC 
infected with HSV-1 was low compared to the percentage infectivity seen in MDDC 
and MDLC. HSV-1 DNA has been shown to carry CpG motifs, hence rendering the 
virus to be highly immunostimulatory via TLR-9 (Lundberg et al., 2003). These results 
are consistent with studies on murine pDC showing TLR-9-dependent recognition of 
HSV DNA (Lund et al., 2003; Hochrein et al., 2004; Krug et al., 2004). However, no 
cytokine production was detected in pDC co-cultured with the Cos-7 cells expressing 
the four glycoproteins, suggesting that the viral DNA is responsible for the TLR9 
activation in pDC and not the viral entry glycoproteins. 
5.4. Conclusion
In this chapter the interaction of the virus and the viral entry glycoproteins with other 
subtypes of DC has been investigated. The results demonstrate clearly that MDLC, 
thought to represent human epidermal LC, mature in response to the virus and the Cos-7 
cells expressing the four entry glycoproteins. However, in contrast to MDDC, these 
cells do not induce a type I IFN or a TH1 response, and therefore, in this form they may 
not play a major role in the immediate response to primary HSV-1 infection. In 
addition, unlike MDDC, interaction between virus and pDC demonstrated clearly that 
the viral glycoproteins do not activate these cells. CHAPTER 6 – GENERAL DISCUSSION162
6.1. Introduction
Previous studies have suggested a model which attempts to explain how DCs overcome 
the ability of infective HSV-1 to inhibit antigen presentation (Pollara, 2005). In this 
model, myeloid DC infected with HSV-1 produce sufficient IFN to prime bystander 
uninfected DC, and to induce maturation and migration of these DC, which cross-
present antigen from dying infected cells. In this thesis this work has been extended. 
One of the ligands of HSV-1 that elicit the activation of the DC and induce the 
signalling changes that bring about type I IFN secretion has been identified. The main 
emphasis of the study was on the viral entry glycoproteins (gB, gD and gHgL) only, and 
how they interact with the DC. Further studies should also look at other surface 
glycoproteins and their interactions with DC. In addition LC and pDC models were 
examined in order to develop a more comprehensive model of the innate immune 
response to HSV-1. 
6.2. HSV-1 entry glycoproteins as inducers for DC maturation
HSV-1 entry occurs when extracellular virions attach to the cells surface via gC and gB, 
and then bind to a gD receptor activating the membrane fusion machinery comprised of 
gB, and the heterodimer gHgL (Campadelli-Fiume G et al., 2000; Spear, 2004; Reske A 
et al., 2007) (fig. 1.2). After this initial step, concomitant virus binding on the cell 
surface and membrane fusion mediated by these glycoproteins is thought to activate 
intracellular immunosignalling processes. Chapter 3 demonstrates clearly that these 
entry glycoproteins function as novel DC maturation inducers, independent of other 
viral components, both in the maturation of MDDC and in secretion of type I IFN. Their 
function seems to require the co-operative interaction of all four glycoproteins, acting 
together presumably as a complex. This complex formation is a known phenomenon in 
HSV and several studies have shown the importance of such complex formation in the 163
glycoprotein function (Avitabile et al., 2007; Atanasiu et al., 2007). However, this is the 
first study to show the importance of the glycoprotein complex in the maturation of DC. 
Several receptors have been shown to associate with the HSV virions in entry and cell 
signalling pathways. HVEM and nectin-1 are two receptors expressed on cells, 
including DC, which are known to interact with the viral glycoprotein D, and to be 
important for viral entry into cells. Studies on cell lines expressing HVEM have also 
demonstrated that interaction of gD with this receptor can lead to the activation of the 
NF-kB signaling pathway (Sciortino MT et al., 2008). In this study, however, the direct 
interaction between gD and HVEM or nectin-1 on the MDDC surface does not appear 
to be essential or sufficient for initiating DC maturation. Other receptors associated with 
HSV-1 signalling, TLR2 and TLR9 where also shown not to be essential in the 
maturation of DC by the glycoproteins, suggesting another receptor(s) must play a role 
(discussed further in section 6.5).  
6.3. Direct and indirect interactions in primary HSV-1 – DC 
interactions
In chapter 4 and 5, the biological consequences and the interaction of the viral 
glycoproteins with different DC subsets were studied. The results clearly demonstrate 
that MDDC infected directly with HSV-1 are inhibited in their ability to induce an 
effective anti-viral immune response. Although HSV-1 infected MDDC produce IFN, 
this response was lower than that produced by HSV-1 infected pDC. MDDC which are 
exposed to viral glycoproteins, are primed to induce an immediate type I IFN response, 
which may not only contribute to the anti-viral state, but also contribute to stimulating a 
strong protective TH1 response. In contrast, MDLC were poor stimulators of type I IFN 
TH1 responses, but did respond to the viral glycoproteins, stimulating the production of 
IL-13. pDC did not respond at all to the viral glycoproteins.164
Together these results support a model, in which the major stimulation of protective T 
cell immunity to HSV-1 could be via DDC. These cells could be exposed to viral 
glycoproteins released from lytic keratinocytes infections, from infected fibroblasts in 
the dermis, or from infected LC that are migrating through the dermis. Ultimately they 
could pick up and cross-present the glycoproteins, and at the same time are capable of 
producing an immediate type I IFN response. In addition to its anti-viral activity, type I 
IFN may also be an important danger signal detected by bystander uninfected DC, 
inducing activation of more APCs (Luft et al., 2002; Pollara et al., 2004a). Possibly 
pDC recruited to the site of infection can produce a stronger type I IFN response, 
induced by HSV DNA. In contrast, any DC infected with virus, or expressing 
glycoproteins, and any LC similarly altered in a similar fashion are inhibited in their 
TH1 stimulating ability, but may drive a TH2 response which may be relevant to the high 
production of antibody that has been observed in infected individuals. Alternatively, 
however, the findings are also consistent with a model where LC infected with HSV-1 
in the epidermis may transport antigen to the LNs, and then transfer the antigen to LN 
resident DC for antigen presentation and T cell priming (Allan et al., 2003) (fig. 6.1). 
Irrespective of the in vivo balance between these two models, these findings add further 
support to the hypothesis explored previously (Pollara, 2005), i.e. that it is the 
“bystander” activated DC, not the infected or directly stimulated form, that act as the 
major APC in viral infection.165
Figure 6.1: Direct and indirect interaction in HSV-1 – DC interactions. Following 
primary HSV-1 infection, viral glycoproteins expressed on infected keratinocytes, 
infected LC are cross-presented (filled black arrows) by DDC. Ultimately, these cells 
migrate (dotted arrows) to the lymph nodes to present the viral antigen to T cells which 
produce a IFN TH1 response. At the same time, these cells produce sufficient type I 
IFN to recruit additional myeloid DC and pDC, where they produce additional type I 
IFN. Alternatively, glycoproteins expressed on infected keratinocytes, infected 
epidermal LC and/or released from lytic cells are cross-presented (filled grey arrows) by 
non-infected LC which migrate to the lymph nodes transferring the antigens to dermal 
DC or to LN resident DC for antigen presentation and T cell priming.166
6.4. Clinical implications
6.4.1. Development of an HSV vaccine
HSV infection can result in a number of severe complications, especially in neonates 
and the immunocompromised (Stewart JA et al., 1995; Jacobs, 1998). Additional 
complications include stromal keratitis, the leading cause of infectious blindness 
(Liesegang, 2001). More recently, epidemiological studies suggest that in the presence 
of HSV infection, specifically HSV-2, the susceptibility and sexual transmission of HIV 
infection is increased. Furthermore, HSV-2 infection may be associated with an increase 
in blood HIV verimia (Schacker et al., 2002; Corey L et al., 2004; Rebbapragada et al., 
2007). Hence, an effective vaccine would be beneficial both in controlling HSV 
morbidity and mortality, as well as beneficial in the control of HIV spread.
Over the years several approaches to the design of an effective HSV vaccine have been 
explored, from live attenuated virus to the use of recombinant viral subunits (Stanberry 
LR, 2004; Koelle DM, 2006). However, to date, all have failed to reach the endpoint of 
protection from infection in clinical trials. In this section the focus is on the 
development of glycoprotein subunit vaccines, which are likely to provide a safer 
alternative to live virus.
Several past efforts have demonstrated promising results in animal models using 
recombinant glycoprotein vaccines, specifically gB and gD, two essential glycoproteins 
that are cross-reactive between HSV-1 and HSV-2 (Peng et al., 1998b; Ghiasi et al., 
1996; Manservigi et al., 2005). Recombinant HSV-1 gD induced an antibody response 
in Japanese macaques, which could be increased following intracutaneous boosting 
(Hirano et al., 2002). A variable T cell response was also detected. Recombinant gB and 
gD proteins have also been used as candidate subunit vaccine in human subjects. Thus 167
far, a combined HSV-2 recombinant gD-gB subunit vaccine with adjuvant, despite 
inducing high titres of specific antibodies, provided only a transient protection to 
infection (Corey et al., 1999). Another recombinant gD vaccine given with a more 
effective adjuvant (AS04), showed resistance to genital herpes in women who were 
seronegative at the time of vaccination to both HSV-1 and HSV-2, however failed in the 
protection of both men (regardless of their HSV serological status at time of 
vaccination) and women who were seropositive to HSV-1 (Stanberry et al., 2002).  
Further studies in animal models demonstrated that the effectivness of the vaccine was 
dependent on the adjuvant which skews towards a strong TH1 response (Bourne et al., 
2003).
Recently in addition to the recombinant protein vaccines, DNA plasmids expressing 
HSV glycoproteins have been considered as potential vaccines (McClements WL et al., 
1996; McClements WL et al., 1997; Flo, 2003). DNA vaccination has significant 
advantages over other alternative immunization methods, because it is capable of 
inducing both arms of the adaptive immune response based upon very efficient delivery 
of heterologous proteins to APC of either transfected or infected cells, hence ensuring 
the transmission of a full activation signal to T cells. In addition, viral antigens may be 
administered together with genes encoding cytokines and chemokines which further 
enhance the function of the APC (Lee et al., 2003a; Lee et al., 2003b). The potency of 
immunity can be amplified further by the combination of DNA vaccines with 
fowlpoxvirus or modified vaccinia virus expressing similar antigens in a “prime-boost” 
strategy (Ramshaw and Ramsay, 2000).
Thus far, however, the design of an effective HSV vaccine based on one, or a 
combination of two, glycoproteins has been unsuccessful. In light of the data presented 168
in this thesis demonstrating the optimum requirement for a complex of all four HSV 
entry glycoproteins for DC stimulation, it could be that the immune stimulation 
achieved is sub-optimal, and that a vaccine containing the complex of all four entry 
glycoproteins may be more successful. However, it should be noted that the 
reconstitution of a functional entry/activation complex in a cell free system has not yet 
been achieved.  
6.4.2. HSV as a gene delivery vector to DC      
Initially HSV was suggested as an ideal vector for gene delivery to the nervous system 
(Lachmann and Efstathiou S, 1997). Its ability to infect several cell types efficiently and 
express multiple engineered genes suggested it to be a suitable candidate for the 
delivery of exogenous genes to DC as well (Coffin et al., 1998). However, in order to 
achieve an effective gene delivery, several viral factors disrupting DC function need to 
be removed. These include ICP47, which is thought to interfere with peptide 
translocation via TAP and subsequent loading on to MHC class I; gB, which may 
interfere with the loading of MHC class II; vhs, which may be responsible for changes 
in DC function by a mechanism involving the degradation of cellular mRNA; ICP27, 
which may be responsible for the shutdown of host protein synthesis and blocking of 
STAT-1, resulting in inhibition of type I IFN production; ICP4, which may be 
responsible for host protein synthesis shut off and to the inhibition of cytokine 
production; and ICP0, which may inhibit nuclear accumulation of IRF3, hence 
interfering with type I IFN signalling. Early studies have suggested that it is possible to 
produce an HSV-1 vector able to efficiently transduce DC which also allows the 
activation of DC necessary for an effective immune response (Samady et al., 2003). 169
These studies have not been followed up, however, and further studies are necessary in 
order to establish an efficient HSV-1 vector.
Another method of gene delivery that has gained much attention in recent years is the 
use of viral amplicon vectors – defective, non-integrative, helper-dependent vectors, 
derived from HSV-1. These viral particles are identical to the wild-type in terms of 
structure, but carry an amplicon plasmid carrying the transgene of interest instead of the 
viral genome. Recent works have looked at this approach for tumour therapy and the 
treatment of neuro-degenerative disorders (Cuchet D et al., 2007). 
The data presented here, demonstrating the efficiency of the HSV-1 surface 
glycoproteins in inducing an immune response in DC, raises the possibility that other 
delivery systems should be considered. One example of this could be virus-like particles
(VLP), which are empty non-infectious viral capsids with a similar morphology to the 
virus from which they have been derived (Petry H et al., 2003). Although most recent 
studies into VLP technology have looked at vaccine development, some research groups 
have demonstrated that VLP could also represent a useful gene therapy delivery system 
(Malboeuf CM et al., 2007). 
6.5. Future work
This project follows from previous work which tried to solve some of the puzzle of the 
interaction between HSV-1 and DC (Pollara, 2005), and, as well as offering some 
answers, has generated many more unresolved questions that would be of interest.
One question that remains unanswered is the nature of the receptor(s) on DC that 
interact with the glycoproteins to initiate a response. In this thesis this has been 
explained by examining known HSV-1 receptors, specifically HVEM, nectin-1 as well 
as TLR2 and TLR9, known to interact with HSV-1 (section 3.2.6). More studies in this 170
area are necessary to try to establish the exact receptor, perhaps looking at the newly 
recognized gB receptor, PILR (Satoh et al., 2008) or the different integrins (Parry et 
al., 2005). However, these studies will have to take into account the possibility of 
receptor redundancy, that different receptors may act in concert in order to deliver the 
activating signal to DC and “receptor switching”, where in the absence of one receptor 
the glycoproteins may interact with another receptor..   
Another area of interest is the interaction between HSV-1 infected keratinocytes and DC 
where a robust in vitro model would be very informative. For example, HaCaT cells are 
known to express the HSV-1 glycoproteins following infection (appendix A), but 
neither the crosstalk between the chemokines/cytokines secreted by these cells and DC 
nor the interaction between the glycoproteins expressed on the HaCaT cells and DC has 
been studied. In vitro models could also be taken further using skin explants and 
analyzing the migratory abilities and the activation of different subsets of DC and/or 
macrophages. In addition the design of appropriate complimentary studies in in vivo
animal models would be useful. 
Finally, for use either as a vector for immunotherapy, or as a HSV-1 vaccine, the 
production of a VLP consisting of the viral glycoproteins should be considered. In 
preliminary studies, an attempt was made to assemble a VLP from 293T cells 
expressing the four HSV-1 entry glycoproteins, and carrying the HIV gag protein and a 
GFP expressing protein. These VLP were found to enter both BHK and 293T cells as 
confirmed by GFP expression (data not shown), but more studies are necessary to 
establish and characterize the interaction with DC. 171
Appendix A – preliminary results
HaCaT cells are highly susceptible to HSV-1 infection showing expression of viral 
glycoproteins. The keratinocyte cell line, HaCaT, was infected with HSV-1/GFP at an 
MOI of 1 and the MFI of GFP and gD expression was measured by FACS in a 24 hour 
time course. The graph represents the mean values from three independent experiments.172
Appendix B – preliminary results
Ex-vivo isolation of human epidermal LC. Human skin was obtained from 
mammoplasty patients with informed consent and local ethical approval. Epidermal and 
dermal sheets were separated and incubated in complete medium supplemented with 
GM-CSF. Migratory LC were harvested from the fluid phase. Cells were stimulated and 
analyzed for CD86 and CD83 maturation markers by flow cytometry. Open dotted 
histogram in top right represents the isotype control. Open histograms represent the 
unstimulated LC; grey histograms represent the stimulated cells.Reference List
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